Difference between revisions of "Gene Editing Patent Application Trends 2024"
Jump to navigation
Jump to search
Wikipatents (talk | contribs) (Updating Gene Editing Patent Application Trends 2024) |
Wikipatents (talk | contribs) (Updating Gene Editing Patent Application Trends 2024) |
||
| Line 1: | Line 1: | ||
== Gene Editing Patent Application Filing Activity == | == Gene Editing Patent Application Filing Activity == | ||
== Gene Editing patent applications in 2024 == | == Gene Editing patent applications in 2024 == | ||
| − | [[File:Gene_Editing_Monthly_Patent_Applications_2024_- | + | [[File:Gene_Editing_Monthly_Patent_Applications_2024_-_Up_to_November 2024.png|border|800px]] |
== Top Technology Areas in Gene Editing == | == Top Technology Areas in Gene Editing == | ||
| − | [[File:Top_Technology_Areas_in_Gene_Editing_2024_- | + | [[File:Top_Technology_Areas_in_Gene_Editing_2024_-_Up_to_November 2024.png|border|800px]] |
=== Top CPC Codes === | === Top CPC Codes === | ||
* [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available) | * [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available) | ||
| − | ** Count: | + | ** Count: 395 patents |
| − | ** Example: [[20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING | + | ** Example: [[20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation)]] |
* [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available) | * [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available) | ||
| − | ** Count: | + | ** Count: 367 patents |
| − | ** Example: [[20240226246. NOVEL OMNI-50 CRISPR NUCLEASE | + | ** Example: [[20240226246. NOVEL OMNI-50 CRISPR NUCLEASE (EmendoBio Inc.)]] |
* [[:Category:CPC_C12N15/86|C12N15/86]] (No explanation available) | * [[:Category:CPC_C12N15/86|C12N15/86]] (No explanation available) | ||
| − | ** Count: | + | ** Count: 236 patents |
| − | ** Example: [[20240226326. COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMS | + | ** Example: [[20240226326. COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMS (Decibel Therapeutics, Inc.)]] |
* [[:Category:CPC_C12N15/11|C12N15/11]] (No explanation available) | * [[:Category:CPC_C12N15/11|C12N15/11]] (No explanation available) | ||
| − | ** Count: | + | ** Count: 201 patents |
| − | ** Example: [[20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING | + | ** Example: [[20240226152. SENOLYTIC CRISPR CAR T CELLS PRODUCED BY CRISPR-CAS9 GENOME EDITING (Wisconsin Alumni Research Foundation)]] |
* [[:Category:CPC_C12N2750/14143|C12N2750/14143]] (No explanation available) | * [[:Category:CPC_C12N2750/14143|C12N2750/14143]] (No explanation available) | ||
| − | ** Count: | + | ** Count: 165 patents |
| − | ** Example: [[20240226332. GENE THERAPY FOR TREM2-ASSOCIATED DISEASES AND DISORDERS | + | ** Example: [[20240226332. GENE THERAPY FOR TREM2-ASSOCIATED DISEASES AND DISORDERS (Eli Lilly and Company)]] |
* [[:Category:CPC_C12N15/907|C12N15/907]] (No explanation available) | * [[:Category:CPC_C12N15/907|C12N15/907]] (No explanation available) | ||
| − | ** Count: | + | ** Count: 124 patents |
| − | ** Example: [[20240226246. NOVEL OMNI-50 CRISPR NUCLEASE | + | ** Example: [[20240226246. NOVEL OMNI-50 CRISPR NUCLEASE (EmendoBio Inc.)]] |
* [[:Category:CPC_A61K48/005|A61K48/005]] (No explanation available) | * [[:Category:CPC_A61K48/005|A61K48/005]] (No explanation available) | ||
| − | ** Count: | + | ** Count: 113 patents |
| − | ** Example: [[20240226326. COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMS | + | ** Example: [[20240226326. COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMS (Decibel Therapeutics, Inc.)]] |
* [[:Category:CPC_C12N2800/80|C12N2800/80]] (No explanation available) | * [[:Category:CPC_C12N2800/80|C12N2800/80]] (No explanation available) | ||
| − | ** Count: | + | ** Count: 104 patents |
| − | ** Example: [[20240226246. NOVEL OMNI-50 CRISPR NUCLEASE | + | ** Example: [[20240226246. NOVEL OMNI-50 CRISPR NUCLEASE (EmendoBio Inc.)]] |
* [[:Category:CPC_C12N15/111|C12N15/111]] (No explanation available) | * [[:Category:CPC_C12N15/111|C12N15/111]] (No explanation available) | ||
| − | ** Count: | + | ** Count: 102 patents |
| − | ** Example: [[20240226334. CORRECTION OF DUCHENNE MUSCULAR DYSTROPHY MUTATIONS WITH ALL-IN-ONE ADENO-ASSOCIATED VIRUS-DELIVERED SINGLE-CUT CRISPR | + | ** Example: [[20240226334. CORRECTION OF DUCHENNE MUSCULAR DYSTROPHY MUTATIONS WITH ALL-IN-ONE ADENO-ASSOCIATED VIRUS-DELIVERED SINGLE-CUT CRISPR (The Board of Regents of The University of Texas System)]] |
* [[:Category:CPC_C12N15/113|C12N15/113]] (No explanation available) | * [[:Category:CPC_C12N15/113|C12N15/113]] (No explanation available) | ||
| − | ** Count: | + | ** Count: 87 patents |
| − | ** Example: [[20240228546. METHODS AND PRODUCTS FOR GENETIC ENGINEERING | + | ** Example: [[20240228546. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM))]] |
== Top Companies in Gene Editing == | == Top Companies in Gene Editing == | ||
| Line 42: | Line 42: | ||
=== [[:Category:The Broad Institute, Inc.|The Broad Institute, Inc.]] === | === [[:Category:The Broad Institute, Inc.|The Broad Institute, Inc.]] === | ||
| − | * Number of Gene Editing patents: | + | * Number of Gene Editing patents: 22 |
* Top CPC codes: | * Top CPC codes: | ||
| − | ** [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available): | + | ** [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available): 17 patents |
** [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available): 16 patents | ** [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available): 16 patents | ||
** [[:Category:CPC_C12N15/907|C12N15/907]] (No explanation available): 11 patents | ** [[:Category:CPC_C12N15/907|C12N15/907]] (No explanation available): 11 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | + | ** [[20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.)]] (20241003) |
| − | ** [[20240327933. CORONAVIRUS RAPID DIAGNOSTICS | + | ** [[20240327933. CORONAVIRUS RAPID DIAGNOSTICS (The Broad Institute, Inc.)]] (20241003) |
| − | ** [[20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS | + | ** [[20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.)]] (20240208) |
=== [[:Category:The Regents of the University of California|The Regents of the University of California]] === | === [[:Category:The Regents of the University of California|The Regents of the University of California]] === | ||
| − | * Number of Gene Editing patents: | + | * Number of Gene Editing patents: 19 |
* Top CPC codes: | * Top CPC codes: | ||
| − | ** [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available): | + | ** [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available): 10 patents |
| − | ** [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available): | + | ** [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available): 10 patents |
| − | ** [[:Category:CPC_C12N15/11|C12N15/11]] (No explanation available): | + | ** [[:Category:CPC_C12N15/11|C12N15/11]] (No explanation available): 7 patents |
* Recent patents: | * Recent patents: | ||
| − | ** [[20240216541. GENE THERAPY FOR ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY | + | ** [[20240216541. GENE THERAPY FOR ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY (The Regents of the University of California)]] (20240704) |
| − | ** [[20240023528. ONE-LOCUS INDUCIBLE PRECISION GUIDED STERILE INSECT TECHNIQUE OR TEMPERATURE-INDUCIBLE PRECISION GUIDED STERILE INSECT TECHNIQUE | + | ** [[20240023528. ONE-LOCUS INDUCIBLE PRECISION GUIDED STERILE INSECT TECHNIQUE OR TEMPERATURE-INDUCIBLE PRECISION GUIDED STERILE INSECT TECHNIQUE (The Regents of the University of California)]] (20240125) |
| − | ** [[20240026321. CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF | + | ** [[20240026321. CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF (The Regents of the University of California)]] (20240125) |
=== [[:Category:Mammoth Biosciences, Inc.|Mammoth Biosciences, Inc.]] === | === [[:Category:Mammoth Biosciences, Inc.|Mammoth Biosciences, Inc.]] === | ||
* Number of Gene Editing patents: 11 | * Number of Gene Editing patents: 11 | ||
| Line 68: | Line 68: | ||
** [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available): 6 patents | ** [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available): 6 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[20240084275. COMPOSITIONS AND METHODS OF USING PROGRAMMABLE NUCLEASES FOR INDUCING CELL DEATH | + | ** [[20240084275. COMPOSITIONS AND METHODS OF USING PROGRAMMABLE NUCLEASES FOR INDUCING CELL DEATH (Mammoth Biosciences, Inc.)]] (20240314) |
| − | ** [[20240218393. VECTORS ENCODING GENE EDITING SYSTEMS AND USES THEREOF | + | ** [[20240218393. VECTORS ENCODING GENE EDITING SYSTEMS AND USES THEREOF (Mammoth Biosciences, Inc.)]] (20240704) |
| − | ** [[20240327812. FUSION EFFECTOR PROTEINS AND USES THEREOF | + | ** [[20240327812. FUSION EFFECTOR PROTEINS AND USES THEREOF (Mammoth Biosciences, Inc.)]] (20241003) |
=== [[:Category:The Trustees of the University of Pennsylvania|The Trustees of the University of Pennsylvania]] === | === [[:Category:The Trustees of the University of Pennsylvania|The Trustees of the University of Pennsylvania]] === | ||
* Number of Gene Editing patents: 11 | * Number of Gene Editing patents: 11 | ||
| Line 78: | Line 78: | ||
** [[:Category:CPC_C12N2750/14143|C12N2750/14143]] (No explanation available): 5 patents | ** [[:Category:CPC_C12N2750/14143|C12N2750/14143]] (No explanation available): 5 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[20240218394. GENE THERAPY FOR OCULAR DISORDERS | + | ** [[20240218394. GENE THERAPY FOR OCULAR DISORDERS (The Trustees of the University of Pennsylvania)]] (20240704) |
| − | ** [[20240316107. Compositions and Methods for Gene Editing in T Cells Using CRISPR/Cpf1 | + | ** [[20240316107. Compositions and Methods for Gene Editing in T Cells Using CRISPR/Cpf1 (The Trustees of the University of Pennsylvania)]] (20240926) |
| − | ** [[20240024510. GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I | + | ** [[20240024510. GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I (The Trustees of the University of Pennsylvania)]] (20240125) |
=== [[:Category:UNIVERSITY OF MASSACHUSETTS|UNIVERSITY OF MASSACHUSETTS]] === | === [[:Category:UNIVERSITY OF MASSACHUSETTS|UNIVERSITY OF MASSACHUSETTS]] === | ||
| − | * Number of Gene Editing patents: | + | * Number of Gene Editing patents: 11 |
| + | * Top CPC codes: | ||
| + | ** [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available): 8 patents | ||
| + | ** [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available): 7 patents | ||
| + | ** [[:Category:CPC_C12N15/907|C12N15/907]] (No explanation available): 5 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240018479. METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE DISEASE WITH IPSC-INDUCED HUMAN SKELETAL MUSCLE STEM CELLS (UNIVERSITY OF MASSACHUSETTS)]] (20240118) | ||
| + | ** [[20240175056. PRIME EDITING-BASED SIMULTANEOUS GENOMIC DELETION AND INSERTION (UNIVERSITY OF MASSACHUSETTS)]] (20240530) | ||
| + | ** [[20240167029. MODIFIED GUIDE RNAS FOR CRISPR GENOME EDITING (UNIVERSITY OF MASSACHUSETTS)]] (20240523) | ||
| + | === [[:Category:THE BROAD INSTITUTE, INC.|THE BROAD INSTITUTE, INC.]] === | ||
| + | * Number of Gene Editing patents: 10 | ||
* Top CPC codes: | * Top CPC codes: | ||
| − | ** [[:Category: | + | ** [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available): 9 patents |
| − | ** [[:Category: | + | ** [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available): 8 patents |
| − | ** [[:Category:CPC_C12N15/ | + | ** [[:Category:CPC_C12N15/102|C12N15/102]] (No explanation available): 5 patents |
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240110165. NOVEL TYPE VI CRISPR ORTHOLOGS AND SYSTEMS (THE BROAD INSTITUTE, INC.)]] (20240404) |
| − | ** [[ | + | ** [[20240318165. TYPE I-B CRISPR-ASSOCIATED TRANSPOSASE SYSTEMS (THE BROAD INSTITUTE, INC.)]] (20240926) |
| − | ** [[ | + | ** [[20240043828. T-DNA MEDIATED GENETIC MODIFICATION (THE BROAD INSTITUTE, INC.)]] (20240208) |
| − | === [[:Category: | + | === [[:Category:Arbor Biotechnologies, Inc.|Arbor Biotechnologies, Inc.]] === |
| − | * Number of Gene Editing patents: | + | * Number of Gene Editing patents: 10 |
* Top CPC codes: | * Top CPC codes: | ||
| − | ** [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available): | + | ** [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available): 10 patents |
| − | ** [[:Category: | + | ** [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available): 10 patents |
| − | ** [[:Category: | + | ** [[:Category:CPC_C12N15/907|C12N15/907]] (No explanation available): 5 patents |
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240261435. GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING TRANSTHYRETIN (TTR) AND USES THEREOF (Arbor Biotechnologies, Inc.)]] (20240808) |
| − | ** [[ | + | ** [[20240011004. COMPOSITIONS COMPRISING A VARIANT CRISPR NUCLEASE POLYPEPTIDE AND USES THEREOF (Arbor Biotechnologies, Inc.)]] (20240111) |
| − | ** [[ | + | ** [[20240409908. NOVEL CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND COMPONENTS (Arbor Biotechnologies, Inc.)]] (20241212) |
| − | === [[:Category: | + | === [[:Category:Massachusetts Institute of Technology|Massachusetts Institute of Technology]] === |
| − | * Number of Gene Editing patents: | + | * Number of Gene Editing patents: 9 |
* Top CPC codes: | * Top CPC codes: | ||
| + | ** [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available): 7 patents | ||
** [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available): 7 patents | ** [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available): 7 patents | ||
| − | + | ** [[:Category:CPC_C12N15/111|C12N15/111]] (No explanation available): 5 patents | |
| − | ** [[:Category:CPC_C12N15/ | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240067957. AUTOCATALYTIC BASE EDITING FOR RNA-RESPONSIVE TRANSLATIONAL CONTROL (Massachusetts Institute of Technology)]] (20240229) |
| − | ** [[ | + | ** [[20240067961. SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE) (Massachusetts Institute of Technology)]] (20240229) |
| − | ** [[ | + | ** [[20240035031. TARGETED TRANS-SPLICING USING CRISPR/CAS13 (Massachusetts Institute of Technology)]] (20240201) |
| − | === [[:Category: | + | === [[:Category:Scribe Therapeutics Inc.|Scribe Therapeutics Inc.]] === |
| − | * Number of Gene Editing patents: | + | * Number of Gene Editing patents: 9 |
* Top CPC codes: | * Top CPC codes: | ||
| + | ** [[:Category:CPC_C12N2310/20|C12N2310/20]] (No explanation available): 9 patents | ||
** [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available): 8 patents | ** [[:Category:CPC_C12N9/22|C12N9/22]] (No explanation available): 8 patents | ||
| − | + | ** [[:Category:CPC_C12N15/907|C12N15/907]] (No explanation available): 5 patents | |
| − | ** [[:Category:CPC_C12N15/ | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240360474. SELF-INACTIVATING VECTORS FOR GENE EDITING (Scribe Therapeutics Inc.)]] (20241031) |
| − | ** [[ | + | ** [[20240026385. ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS (Scribe Therapeutics Inc.)]] (20240125) |
| − | ** [[ | + | ** [[20240026386. COMPOSITIONS AND METHODS FOR THE TARGETING OF BCL11A (Scribe Therapeutics Inc.)]] (20240125) |
=== [[:Category:INBIOSE N.V.|INBIOSE N.V.]] === | === [[:Category:INBIOSE N.V.|INBIOSE N.V.]] === | ||
| − | * Number of Gene Editing patents: | + | * Number of Gene Editing patents: 9 |
* Top CPC codes: | * Top CPC codes: | ||
** [[:Category:CPC_C12N9/1081|C12N9/1081]] (No explanation available): 5 patents | ** [[:Category:CPC_C12N9/1081|C12N9/1081]] (No explanation available): 5 patents | ||
| − | ** [[:Category:CPC_C12P19/12|C12P19/12]] (No explanation available): | + | ** [[:Category:CPC_C12P19/12|C12P19/12]] (No explanation available): 5 patents |
| − | ** [[:Category:CPC_C12N9/1051|C12N9/1051]] (No explanation available): | + | ** [[:Category:CPC_C12N9/1051|C12N9/1051]] (No explanation available): 5 patents |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240191270. FERMENTATIVE PRODUCTION (INBIOSE N.V.)]] (20240613) |
| − | ** [[ | + | ** [[20240084347. CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS (INBIOSE N.V.)]] (20240314) |
| − | ** [[ | + | ** [[20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES (INBIOSE N.V.)]] (20241003) |
== New Companies in Gene Editing (Last Month) == | == New Companies in Gene Editing (Last Month) == | ||
| Line 152: | Line 152: | ||
* [[:Category:CPC_G06N3/088|G06N3/088]] (No explanation available) | * [[:Category:CPC_G06N3/088|G06N3/088]] (No explanation available) | ||
** Count: 1 patents | ** Count: 1 patents | ||
| − | ** Example: [[20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS | + | ** Example: [[20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.)]] |
* [[:Category:CPC_G06F18/2413|G06F18/2413]] (No explanation available) | * [[:Category:CPC_G06F18/2413|G06F18/2413]] (No explanation available) | ||
** Count: 1 patents | ** Count: 1 patents | ||
| − | ** Example: [[20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS | + | ** Example: [[20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.)]] |
* [[:Category:CPC_G06F18/295|G06F18/295]] (No explanation available) | * [[:Category:CPC_G06F18/295|G06F18/295]] (No explanation available) | ||
** Count: 1 patents | ** Count: 1 patents | ||
| − | ** Example: [[20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS | + | ** Example: [[20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.)]] |
* [[:Category:CPC_G06F18/231|G06F18/231]] (No explanation available) | * [[:Category:CPC_G06F18/231|G06F18/231]] (No explanation available) | ||
** Count: 1 patents | ** Count: 1 patents | ||
| − | ** Example: [[20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS | + | ** Example: [[20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.)]] |
* [[:Category:CPC_G16B40/30|G16B40/30]] (No explanation available) | * [[:Category:CPC_G16B40/30|G16B40/30]] (No explanation available) | ||
** Count: 1 patents | ** Count: 1 patents | ||
| − | ** Example: [[20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS | + | ** Example: [[20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.)]] |
* [[:Category:CPC_G09B19/00|G09B19/00]] (No explanation available) | * [[:Category:CPC_G09B19/00|G09B19/00]] (No explanation available) | ||
** Count: 1 patents | ** Count: 1 patents | ||
| − | ** Example: [[20240046217. TALENT MOBILITY PLATFORM | + | ** Example: [[20240046217. TALENT MOBILITY PLATFORM (ADP, Inc.)]] |
* [[:Category:CPC_A61L2430/02|A61L2430/02]] (No explanation available) | * [[:Category:CPC_A61L2430/02|A61L2430/02]] (No explanation available) | ||
** Count: 1 patents | ** Count: 1 patents | ||
| − | ** Example: [[20240043818. Engineered Cells for Increased Collagen Production | + | ** Example: [[20240043818. Engineered Cells for Increased Collagen Production (Northeastern University)]] |
* [[:Category:CPC_A61L2430/16|A61L2430/16]] (No explanation available) | * [[:Category:CPC_A61L2430/16|A61L2430/16]] (No explanation available) | ||
** Count: 1 patents | ** Count: 1 patents | ||
| − | ** Example: [[20240043818. Engineered Cells for Increased Collagen Production | + | ** Example: [[20240043818. Engineered Cells for Increased Collagen Production (Northeastern University)]] |
* [[:Category:CPC_A61L26/0033|A61L26/0033]] (No explanation available) | * [[:Category:CPC_A61L26/0033|A61L26/0033]] (No explanation available) | ||
** Count: 1 patents | ** Count: 1 patents | ||
| − | ** Example: [[20240043818. Engineered Cells for Increased Collagen Production | + | ** Example: [[20240043818. Engineered Cells for Increased Collagen Production (Northeastern University)]] |
* [[:Category:CPC_A61L27/24|A61L27/24]] (No explanation available) | * [[:Category:CPC_A61L27/24|A61L27/24]] (No explanation available) | ||
** Count: 1 patents | ** Count: 1 patents | ||
| − | ** Example: [[20240043818. Engineered Cells for Increased Collagen Production | + | ** Example: [[20240043818. Engineered Cells for Increased Collagen Production (Northeastern University)]] |
== Top Companies in Emerging Gene Editing Technologies == | == Top Companies in Emerging Gene Editing Technologies == | ||
| Line 192: | Line 192: | ||
=== [[:Category:Feng Zhang|Feng Zhang of Cambridge MA (US)]] === | === [[:Category:Feng Zhang|Feng Zhang of Cambridge MA (US)]] === | ||
| − | * Number of Gene Editing patents: | + | * Number of Gene Editing patents: 21 |
* Top companies: | * Top companies: | ||
** [[:Category:The Broad Institute, Inc.|The Broad Institute, Inc.]]: 12 patents | ** [[:Category:The Broad Institute, Inc.|The Broad Institute, Inc.]]: 12 patents | ||
| − | ** [[:Category:THE BROAD INSTITUTE, INC.|THE BROAD INSTITUTE, INC.]]: | + | ** [[:Category:THE BROAD INSTITUTE, INC.|THE BROAD INSTITUTE, INC.]]: 9 patents |
| + | * Recent patents: | ||
| + | ** [[20240318165. TYPE I-B CRISPR-ASSOCIATED TRANSPOSASE SYSTEMS (THE BROAD INSTITUTE, INC.)]] (20240926) | ||
| + | ** [[20240043828. T-DNA MEDIATED GENETIC MODIFICATION (THE BROAD INSTITUTE, INC.)]] (20240208) | ||
| + | ** [[20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.)]] (20240208) | ||
| + | === [[:Category:Sean HIGGINS|Sean HIGGINS of Alameda CA (US)]] === | ||
| + | * Number of Gene Editing patents: 9 | ||
| + | * Top companies: | ||
| + | ** [[:Category:Scribe Therapeutics Inc.|Scribe Therapeutics Inc.]]: 9 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240360474. SELF-INACTIVATING VECTORS FOR GENE EDITING (Scribe Therapeutics Inc.)]] (20241031) | ||
| + | ** [[20240026385. ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS (Scribe Therapeutics Inc.)]] (20240125) | ||
| + | ** [[20240026386. COMPOSITIONS AND METHODS FOR THE TARGETING OF BCL11A (Scribe Therapeutics Inc.)]] (20240125) | ||
| + | === [[:Category:Sarah DENNY|Sarah DENNY of San Francisco CA (US)]] === | ||
| + | * Number of Gene Editing patents: 9 | ||
| + | * Top companies: | ||
| + | ** [[:Category:Scribe Therapeutics Inc.|Scribe Therapeutics Inc.]]: 9 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240360474. SELF-INACTIVATING VECTORS FOR GENE EDITING (Scribe Therapeutics Inc.)]] (20241031) |
| − | ** [[ | + | ** [[20240026385. ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS (Scribe Therapeutics Inc.)]] (20240125) |
| − | ** [[ | + | ** [[20240026386. COMPOSITIONS AND METHODS FOR THE TARGETING OF BCL11A (Scribe Therapeutics Inc.)]] (20240125) |
| − | === [[:Category: | + | === [[:Category:Benjamin OAKES|Benjamin OAKES of El Cerrito CA (US)]] === |
| − | * Number of Gene Editing patents: | + | * Number of Gene Editing patents: 9 |
* Top companies: | * Top companies: | ||
| − | ** [[:Category: | + | ** [[:Category:Scribe Therapeutics Inc.|Scribe Therapeutics Inc.]]: 9 patents |
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240360474. SELF-INACTIVATING VECTORS FOR GENE EDITING (Scribe Therapeutics Inc.)]] (20241031) |
| − | ** [[ | + | ** [[20240026385. ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS (Scribe Therapeutics Inc.)]] (20240125) |
| − | ** [[ | + | ** [[20240026386. COMPOSITIONS AND METHODS FOR THE TARGETING OF BCL11A (Scribe Therapeutics Inc.)]] (20240125) |
| − | === [[:Category: | + | === [[:Category:Joeri Beauprez|Joeri Beauprez]] === |
| − | * Number of Gene Editing patents: | + | * Number of Gene Editing patents: 9 |
* Top companies: | * Top companies: | ||
| − | ** [[:Category: | + | ** [[:Category:INBIOSE N.V.|INBIOSE N.V.]]: 9 patents |
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240191270. FERMENTATIVE PRODUCTION (INBIOSE N.V.)]] (20240613) |
| − | ** [[ | + | ** [[20240084347. CELLULAR PRODUCTION OF GLYCOSYLATED PRODUCTS (INBIOSE N.V.)]] (20240314) |
| − | ** [[ | + | ** [[20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES (INBIOSE N.V.)]] (20241003) |
=== [[:Category:Jonathan Gootenberg|Jonathan Gootenberg of Cambridge MA (US)]] === | === [[:Category:Jonathan Gootenberg|Jonathan Gootenberg of Cambridge MA (US)]] === | ||
| − | * Number of Gene Editing patents: | + | * Number of Gene Editing patents: 8 |
* Top companies: | * Top companies: | ||
** [[:Category:Massachusetts Institute of Technology|Massachusetts Institute of Technology]]: 4 patents | ** [[:Category:Massachusetts Institute of Technology|Massachusetts Institute of Technology]]: 4 patents | ||
| Line 223: | Line 239: | ||
** [[:Category:MASSACHUSETTS INSTITUTE OF TECHNOLOGY|MASSACHUSETTS INSTITUTE OF TECHNOLOGY]]: 1 patents | ** [[:Category:MASSACHUSETTS INSTITUTE OF TECHNOLOGY|MASSACHUSETTS INSTITUTE OF TECHNOLOGY]]: 1 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[20240067961. SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE) | + | ** [[20240067961. SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE) (Massachusetts Institute of Technology)]] (20240229) |
| − | ** [[20240191223. TYPE VI CRISPR ORTHOLOGS AND SYSTEMS | + | ** [[20240191223. TYPE VI CRISPR ORTHOLOGS AND SYSTEMS (The Broad Institute, Inc.)]] (20240613) |
| − | ** [[20240327933. CORONAVIRUS RAPID DIAGNOSTICS | + | ** [[20240327933. CORONAVIRUS RAPID DIAGNOSTICS (The Broad Institute, Inc.)]] (20241003) |
=== [[:Category:David R. Liu|David R. Liu of Cambridge MA (US)]] === | === [[:Category:David R. Liu|David R. Liu of Cambridge MA (US)]] === | ||
| − | * Number of Gene Editing patents: | + | * Number of Gene Editing patents: 8 |
* Top companies: | * Top companies: | ||
| − | ** [[:Category:The Broad Institute, Inc.|The Broad Institute, Inc.]]: | + | ** [[:Category:The Broad Institute, Inc.|The Broad Institute, Inc.]]: 4 patents |
** [[:Category:President and Fellows of Harvard College|President and Fellows of Harvard College]]: 2 patents | ** [[:Category:President and Fellows of Harvard College|President and Fellows of Harvard College]]: 2 patents | ||
** [[:Category:President and Fellows of Harvard College|President and Fellows of Harvard College]]: 1 patents | ** [[:Category:President and Fellows of Harvard College|President and Fellows of Harvard College]]: 1 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[20240344055. METHODS AND SYSTEMS FOR MODIFYING THE CRUMBS HOMOLOGUE-1 (CRB1) GENE | + | ** [[20240344055. METHODS AND SYSTEMS FOR MODIFYING THE CRUMBS HOMOLOGUE-1 (CRB1) GENE (The Trustees of Columbia University in the City of New York)]] (20241017) |
| − | ** [[20240110166. EDITING OF CCR5 RECEPTOR GENE TO PROTECT AGAINST HIV INFECTION | + | ** [[20240110166. EDITING OF CCR5 RECEPTOR GENE TO PROTECT AGAINST HIV INFECTION (President and Fellows of Harvard College)]] (20240404) |
| − | ** [[20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | + | ** [[20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.)]] (20241003) |
| − | === [[:Category: | + | === [[:Category:Benjamin Julius RAUCH|Benjamin Julius RAUCH of San Francisco CA (US)]] === |
* Number of Gene Editing patents: 7 | * Number of Gene Editing patents: 7 | ||
* Top companies: | * Top companies: | ||
| − | ** [[:Category: | + | ** [[:Category:Mammoth Biosciences, Inc.|Mammoth Biosciences, Inc.]]: 7 patents |
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240173433. PROGRAMMABLE NUCLEASES AND METHODS OF USE (Mammoth Biosciences, Inc.)]] (20240530) |
| − | ** [[ | + | ** [[20240191280. ENHANCED GUIDE NUCLEIC ACIDS AND METHODS OF USE (Mammoth Biosciences, Inc.)]] (20240613) |
| − | ** [[ | + | ** [[20240191281. PROGRAMMABLE NUCLEASES AND METHODS OF USE (Mammoth Biosciences, Inc.)]] (20240613) |
| − | === [[:Category: | + | === [[:Category:Omar Abudayyeh|Omar Abudayyeh of Cambridge MA (US)]] === |
* Number of Gene Editing patents: 7 | * Number of Gene Editing patents: 7 | ||
* Top companies: | * Top companies: | ||
| − | ** [[:Category:Scribe Therapeutics Inc.|Scribe Therapeutics Inc.]]: | + | ** [[:Category:Massachusetts Institute of Technology|Massachusetts Institute of Technology]]: 4 patents |
| + | ** [[:Category:MASSACHUSETTS INSTITUTE OF TECHNOLOGY|MASSACHUSETTS INSTITUTE OF TECHNOLOGY]]: 1 patents | ||
| + | ** [[:Category:THE BROAD INSTITUTE, INC.|THE BROAD INSTITUTE, INC.]]: 1 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240132883. RNA-TRIGGERED PROTEIN CLEAVAGE AND APPLICATIONS BY THE CRISPR CAS7-11-CSX29 COMPLEX (Massachusetts Institute of Technology)]] (20240425) | ||
| + | ** [[20240093193. DEAD GUIDES FOR CRISPR TRANSCRIPTION FACTORS (The Broad Institute, Inc.)]] (20240321) | ||
| + | ** [[20240067961. SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE) (Massachusetts Institute of Technology)]] (20240229) | ||
| + | === [[:Category:Brett T. STAAHL|Brett T. STAAHL of Tiburon CA (US)]] === | ||
| + | * Number of Gene Editing patents: 6 | ||
| + | * Top companies: | ||
| + | ** [[:Category:Scribe Therapeutics Inc.|Scribe Therapeutics Inc.]]: 6 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240360474. SELF-INACTIVATING VECTORS FOR GENE EDITING (Scribe Therapeutics Inc.)]] (20241031) | ||
| + | ** [[20240026385. ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS (Scribe Therapeutics Inc.)]] (20240125) | ||
| + | ** [[20240026386. COMPOSITIONS AND METHODS FOR THE TARGETING OF BCL11A (Scribe Therapeutics Inc.)]] (20240125) | ||
| + | === [[:Category:Lucas Benjamin HARRINGTON|Lucas Benjamin HARRINGTON of San Francisco CA (US)]] === | ||
| + | * Number of Gene Editing patents: 6 | ||
| + | * Top companies: | ||
| + | ** [[:Category:Mammoth Biosciences, Inc.|Mammoth Biosciences, Inc.]]: 6 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240084275. COMPOSITIONS AND METHODS OF USING PROGRAMMABLE NUCLEASES FOR INDUCING CELL DEATH (Mammoth Biosciences, Inc.)]] (20240314) |
| − | ** [[ | + | ** [[20240218393. VECTORS ENCODING GENE EDITING SYSTEMS AND USES THEREOF (Mammoth Biosciences, Inc.)]] (20240704) |
| − | ** [[ | + | ** [[20240327812. FUSION EFFECTOR PROTEINS AND USES THEREOF (Mammoth Biosciences, Inc.)]] (20241003) |
| − | === [[:Category: | + | === [[:Category:Chenglong HAO|Chenglong HAO]] === |
| − | * Number of Gene Editing patents: | + | * Number of Gene Editing patents: 6 |
* Top companies: | * Top companies: | ||
| − | ** [[:Category: | + | ** [[:Category:SHENZHEN METALENX TECHNOLOGY CO.,LTD|SHENZHEN METALENX TECHNOLOGY CO.,LTD]]: 5 patents |
| + | ** [[:Category:SHENZHEN METALENX TECHNOLOGY CO., LTD|SHENZHEN METALENX TECHNOLOGY CO., LTD]]: 1 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240345463. POINT CLOUD PROJECTION SYSTEM (SHENZHEN METALENX TECHNOLOGY CO.,LTD)]] (20241017) |
| − | ** [[ | + | ** [[20240315540. ENDOSCOPIC PROBE, ENDOSCOPE AND METHOD OF SCANNING CONTROL (SHENZHEN METALENX TECHNOLOGY CO.,LTD)]] (20240926) |
| − | ** [[ | + | ** [[20240319016. METALENS ARRAY AND WAVEFRONT SENSOR SYSTEM (SHENZHEN METALENX TECHNOLOGY CO.,LTD)]] (20240926) |
| − | === [[:Category: | + | === [[:Category:Fengze TAN|Fengze TAN]] === |
* Number of Gene Editing patents: 6 | * Number of Gene Editing patents: 6 | ||
* Top companies: | * Top companies: | ||
| − | ** [[:Category: | + | ** [[:Category:SHENZHEN METALENX TECHNOLOGY CO.,LTD|SHENZHEN METALENX TECHNOLOGY CO.,LTD]]: 5 patents |
| − | ** [[:Category: | + | ** [[:Category:SHENZHEN METALENX TECHNOLOGY CO., LTD|SHENZHEN METALENX TECHNOLOGY CO., LTD]]: 1 patents |
| − | |||
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240345463. POINT CLOUD PROJECTION SYSTEM (SHENZHEN METALENX TECHNOLOGY CO.,LTD)]] (20241017) |
| − | ** [[ | + | ** [[20240315540. ENDOSCOPIC PROBE, ENDOSCOPE AND METHOD OF SCANNING CONTROL (SHENZHEN METALENX TECHNOLOGY CO.,LTD)]] (20240926) |
| − | ** [[ | + | ** [[20240319016. METALENS ARRAY AND WAVEFRONT SENSOR SYSTEM (SHENZHEN METALENX TECHNOLOGY CO.,LTD)]] (20240926) |
| − | === [[:Category: | + | === [[:Category:Jian ZHU|Jian ZHU]] === |
* Number of Gene Editing patents: 6 | * Number of Gene Editing patents: 6 | ||
* Top companies: | * Top companies: | ||
| − | ** [[:Category: | + | ** [[:Category:SHENZHEN METALENX TECHNOLOGY CO.,LTD|SHENZHEN METALENX TECHNOLOGY CO.,LTD]]: 5 patents |
| + | ** [[:Category:SHENZHEN METALENX TECHNOLOGY CO., LTD|SHENZHEN METALENX TECHNOLOGY CO., LTD]]: 1 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240345463. POINT CLOUD PROJECTION SYSTEM (SHENZHEN METALENX TECHNOLOGY CO.,LTD)]] (20241017) |
| − | ** [[ | + | ** [[20240315540. ENDOSCOPIC PROBE, ENDOSCOPE AND METHOD OF SCANNING CONTROL (SHENZHEN METALENX TECHNOLOGY CO.,LTD)]] (20240926) |
| − | ** [[ | + | ** [[20240319016. METALENS ARRAY AND WAVEFRONT SENSOR SYSTEM (SHENZHEN METALENX TECHNOLOGY CO.,LTD)]] (20240926) |
=== [[:Category:James M. Wilson|James M. Wilson of Philadelphia PA (US)]] === | === [[:Category:James M. Wilson|James M. Wilson of Philadelphia PA (US)]] === | ||
* Number of Gene Editing patents: 6 | * Number of Gene Editing patents: 6 | ||
| Line 283: | Line 318: | ||
** [[:Category:The Trustees of the University of Pennsylvania|The Trustees of the University of Pennsylvania]]: 6 patents | ** [[:Category:The Trustees of the University of Pennsylvania|The Trustees of the University of Pennsylvania]]: 6 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[20240197916. COMPOSITIONS AND METHODS FOR IN VIVO NUCLEASE-MEDIATED GENE TARGETING FOR THE TREATMENT OF GENETIC DISORDERS | + | ** [[20240197916. COMPOSITIONS AND METHODS FOR IN VIVO NUCLEASE-MEDIATED GENE TARGETING FOR THE TREATMENT OF GENETIC DISORDERS (The Trustees of the University of Pennsylvania)]] (20240620) |
| − | ** [[20240016903. GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE II | + | ** [[20240016903. GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE II (The Trustees of the University of Pennsylvania)]] (20240118) |
| − | ** [[20240024510. GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I | + | ** [[20240024510. GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I (The Trustees of the University of Pennsylvania)]] (20240125) |
| + | === [[:Category:Natalia SAVELIEVA|Natalia SAVELIEVA]] === | ||
| + | * Number of Gene Editing patents: 6 | ||
| + | * Top companies: | ||
| + | ** [[:Category:CELL AND GENE THERAPY LTD|CELL AND GENE THERAPY LTD]]: 6 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240366787. Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of NOS2, NOS3, VIP, KCNMA1, and CGRP genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-NOS2, or Escherichia coli strain SCS110-AF/VTvaf17-NOS3, or Escherichia coli strain SCS110-AF/VTvaf17-VIP, or Escherichia coli strain SCS110-AF/VTvaf17-KCNMA1, or Escherichia coli strain SCS110-AF/V (CELL AND GENE THERAPY LTD)]] (20241107) | ||
| + | ** [[20240060083. Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of SHH, CTNNB1, NOG, and WNT7A genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-SHH, or Escherichia coli strain SCS110-AF/VTvaf17-CTNNB1, or Escherichia coli strain SCS110-AF/VTvaf17-NOG, or Escherichia coli strain SCS110-AF/VTvaf17-WNT7A carrying the gene therapy DNA vector, method (CELL AND GENE THERAPY LTD)]] (20240222) | ||
| + | ** [[20240325569. Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of BDNF, VEGFA, BFGF, NGF, GDNF, NT3, CNTF, and IGF1 genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-BDNF, or Escherichia coli strain SCS110-AF/VTvaf17-VEGFA, or Escherichia coli strain SCS110-AF/VTvaf17-BFGF, or Escherichia coli strain SCS110-AF/VTvaf17-NGF, or Escherichia coli str (CELL AND GENE THERAPY LTD)]] (20241003) | ||
| + | === [[:Category:Jesse Salk|Jesse Salk of Seattle WA (US)]] === | ||
| + | * Number of Gene Editing patents: 6 | ||
| + | * Top companies: | ||
| + | ** [[:Category:UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION|UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION]]: 6 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240368692. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION)]] (20241107) | ||
| + | ** [[20240035088. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION)]] (20240201) | ||
| + | ** [[20240084385. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION)]] (20240314) | ||
| + | === [[:Category:Lawrence A. Loeb|Lawrence A. Loeb of Bellevue WA (US)]] === | ||
| + | * Number of Gene Editing patents: 6 | ||
| + | * Top companies: | ||
| + | ** [[:Category:UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION|UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION]]: 6 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240368692. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION)]] (20241107) | ||
| + | ** [[20240035088. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION)]] (20240201) | ||
| + | ** [[20240084385. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION)]] (20240314) | ||
| + | === [[:Category:Michael Schmitt|Michael Schmitt of Seattle WA (US)]] === | ||
| + | * Number of Gene Editing patents: 6 | ||
| + | * Top companies: | ||
| + | ** [[:Category:UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION|UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION]]: 6 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240368692. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION)]] (20241107) | ||
| + | ** [[20240035088. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION)]] (20240201) | ||
| + | ** [[20240084385. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION)]] (20240314) | ||
=== [[:Category:Aaron DELOUGHERY|Aaron DELOUGHERY of San Francisco CA (US)]] === | === [[:Category:Aaron DELOUGHERY|Aaron DELOUGHERY of San Francisco CA (US)]] === | ||
* Number of Gene Editing patents: 5 | * Number of Gene Editing patents: 5 | ||
| Line 291: | Line 358: | ||
** [[:Category:Mammoth Biosciences, Inc.|Mammoth Biosciences, Inc.]]: 5 patents | ** [[:Category:Mammoth Biosciences, Inc.|Mammoth Biosciences, Inc.]]: 5 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[20240175059. EFFECTOR PROTEINS AND METHODS OF USE | + | ** [[20240175059. EFFECTOR PROTEINS AND METHODS OF USE (Mammoth Biosciences, Inc.)]] (20240530) |
| − | ** [[20240191280. ENHANCED GUIDE NUCLEIC ACIDS AND METHODS OF USE | + | ** [[20240191280. ENHANCED GUIDE NUCLEIC ACIDS AND METHODS OF USE (Mammoth Biosciences, Inc.)]] (20240613) |
| − | ** [[20240191281. PROGRAMMABLE NUCLEASES AND METHODS OF USE | + | ** [[20240191281. PROGRAMMABLE NUCLEASES AND METHODS OF USE (Mammoth Biosciences, Inc.)]] (20240613) |
=== [[:Category:David PAEZ-ESPINO|David PAEZ-ESPINO of Concord CA (US)]] === | === [[:Category:David PAEZ-ESPINO|David PAEZ-ESPINO of Concord CA (US)]] === | ||
* Number of Gene Editing patents: 5 | * Number of Gene Editing patents: 5 | ||
| Line 299: | Line 366: | ||
** [[:Category:Mammoth Biosciences, Inc.|Mammoth Biosciences, Inc.]]: 5 patents | ** [[:Category:Mammoth Biosciences, Inc.|Mammoth Biosciences, Inc.]]: 5 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[20240271113. EFFECTOR PROTEINS AND METHODS OF USE | + | ** [[20240271113. EFFECTOR PROTEINS AND METHODS OF USE (Mammoth Biosciences, Inc.)]] (20240815) |
| − | ** [[20240131187. EFFECTOR PROTEINS, EFFECTOR PARTNERS, COMPOSITIONS, SYSTEMS AND METHODS OF USE THEREOF | + | ** [[20240131187. EFFECTOR PROTEINS, EFFECTOR PARTNERS, COMPOSITIONS, SYSTEMS AND METHODS OF USE THEREOF (Mammoth Biosciences, Inc.)]] (20240425) |
| − | ** [[20240191281. PROGRAMMABLE NUCLEASES AND METHODS OF USE | + | ** [[20240191281. PROGRAMMABLE NUCLEASES AND METHODS OF USE (Mammoth Biosciences, Inc.)]] (20240613) |
| − | === [[:Category: | + | === [[:Category:Michael Coyle|Michael Coyle of Chapel Hill NC (US)]] === |
| + | * Number of Gene Editing patents: 5 | ||
| + | * Top companies: | ||
| + | ** [[:Category:LifeEDIT Therapeutics, Inc.|LifeEDIT Therapeutics, Inc.]]: 5 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240376456. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.)]] (20241114) | ||
| + | ** [[20240401084. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.)]] (20241205) | ||
| + | ** [[20240026384. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.)]] (20240125) | ||
| + | === [[:Category:Alexandra Briner Crawley|Alexandra Briner Crawley of Cary NC (US)]] === | ||
| + | * Number of Gene Editing patents: 5 | ||
| + | * Top companies: | ||
| + | ** [[:Category:LifeEDIT Therapeutics, Inc.|LifeEDIT Therapeutics, Inc.]]: 5 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240376456. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.)]] (20241114) | ||
| + | ** [[20240401084. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.)]] (20241205) | ||
| + | ** [[20240026384. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.)]] (20240125) | ||
| + | === [[:Category:Tedd D. Elich|Tedd D. Elich of Durham NC (US)]] === | ||
| + | * Number of Gene Editing patents: 5 | ||
| + | * Top companies: | ||
| + | ** [[:Category:LifeEDIT Therapeutics, Inc.|LifeEDIT Therapeutics, Inc.]]: 5 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240376456. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.)]] (20241114) | ||
| + | ** [[20240401084. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.)]] (20241205) | ||
| + | ** [[20240026384. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.)]] (20240125) | ||
| + | === [[:Category:Pieter Coussement|Pieter Coussement]] === | ||
* Number of Gene Editing patents: 5 | * Number of Gene Editing patents: 5 | ||
* Top companies: | * Top companies: | ||
| − | ** [[:Category: | + | ** [[:Category:INBIOSE N.V.|INBIOSE N.V.]]: 5 patents |
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240368651. CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES (INBIOSE N.V.)]] (20241107) |
| − | ** [[ | + | ** [[20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL (INBIOSE N.V.)]] (20240627) |
| − | ** [[ | + | ** [[20240191270. FERMENTATIVE PRODUCTION (INBIOSE N.V.)]] (20240613) |
| − | === [[:Category: | + | === [[:Category:Thomas Decoene|Thomas Decoene]] === |
* Number of Gene Editing patents: 5 | * Number of Gene Editing patents: 5 | ||
* Top companies: | * Top companies: | ||
| − | ** [[:Category: | + | ** [[:Category:INBIOSE N.V.|INBIOSE N.V.]]: 5 patents |
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240368651. CELLULAR PRODUCTION OF DI- AND/OR OLIGOSACCHARIDES (INBIOSE N.V.)]] (20241107) |
| − | ** [[ | + | ** [[20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL (INBIOSE N.V.)]] (20240627) |
| − | ** [[ | + | ** [[20240191270. FERMENTATIVE PRODUCTION (INBIOSE N.V.)]] (20240613) |
| − | === [[:Category: | + | === [[:Category:Annelies Vercauteren|Annelies Vercauteren]] === |
* Number of Gene Editing patents: 5 | * Number of Gene Editing patents: 5 | ||
* Top companies: | * Top companies: | ||
| − | ** [[:Category: | + | ** [[:Category:INBIOSE N.V.|INBIOSE N.V.]]: 5 patents |
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL (INBIOSE N.V.)]] (20240627) |
| − | ** [[ | + | ** [[20240035004. VARIANT SUCROSE PERMEASE POLYPEPTIDES (INBIOSE N.V.)]] (20240201) |
| − | ** [[ | + | ** [[20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES (INBIOSE N.V.)]] (20241003) |
| − | === [[:Category: | + | === [[:Category:Isabel COLIN|Isabel COLIN of Oakland CA (US)]] === |
* Number of Gene Editing patents: 5 | * Number of Gene Editing patents: 5 | ||
* Top companies: | * Top companies: | ||
| − | ** [[:Category: | + | ** [[:Category:Scribe Therapeutics Inc.|Scribe Therapeutics Inc.]]: 5 patents |
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240360474. SELF-INACTIVATING VECTORS FOR GENE EDITING (Scribe Therapeutics Inc.)]] (20241031) |
| − | ** [[ | + | ** [[20240026385. ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS (Scribe Therapeutics Inc.)]] (20240125) |
| − | ** [[ | + | ** [[20240026386. COMPOSITIONS AND METHODS FOR THE TARGETING OF BCL11A (Scribe Therapeutics Inc.)]] (20240125) |
=== [[:Category:Feng ZHANG|Feng ZHANG of Cambridge MA (US)]] === | === [[:Category:Feng ZHANG|Feng ZHANG of Cambridge MA (US)]] === | ||
* Number of Gene Editing patents: 5 | * Number of Gene Editing patents: 5 | ||
| Line 339: | Line 430: | ||
** [[:Category:The Broad Institute, Inc.|The Broad Institute, Inc.]]: 5 patents | ** [[:Category:The Broad Institute, Inc.|The Broad Institute, Inc.]]: 5 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[20240035007. SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH OPTIMIZED FUNCTIONAL CRISPR-CAS SYSTEMS | + | ** [[20240035007. SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH OPTIMIZED FUNCTIONAL CRISPR-CAS SYSTEMS (The Broad Institute, Inc.)]] (20240201) |
| − | ** [[20240035048. DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTIC APPLICATIONS | + | ** [[20240035048. DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTIC APPLICATIONS (The Broad Institute, Inc.)]] (20240201) |
| − | ** [[20240084364. CRISPR ENZYMES AND SYSTEMS | + | ** [[20240084364. CRISPR ENZYMES AND SYSTEMS (The Broad Institute, Inc.)]] (20240314) |
| + | === [[:Category:Théophile OHLMANN|Théophile OHLMANN]] === | ||
| + | * Number of Gene Editing patents: 4 | ||
| + | * Top companies: | ||
| + | ** [[:Category:Institut National De La Sante Et De La Recherche Medicale (INSERM)|Institut National De La Sante Et De La Recherche Medicale (INSERM)]]: 4 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240409588. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM))]] (20241212) | ||
| + | ** [[20240132547. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM))]] (20240425) | ||
| + | ** [[20240109940. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM))]] (20240404) | ||
| + | === [[:Category:Philippe MANGEOT|Philippe MANGEOT]] === | ||
| + | * Number of Gene Editing patents: 4 | ||
| + | * Top companies: | ||
| + | ** [[:Category:Institut National De La Sante Et De La Recherche Medicale (INSERM)|Institut National De La Sante Et De La Recherche Medicale (INSERM)]]: 4 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240409588. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM))]] (20241212) | ||
| + | ** [[20240132547. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM))]] (20240425) | ||
| + | ** [[20240109940. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM))]] (20240404) | ||
| + | === [[:Category:Emiliano RICCI|Emiliano RICCI]] === | ||
| + | * Number of Gene Editing patents: 4 | ||
| + | * Top companies: | ||
| + | ** [[:Category:Institut National De La Sante Et De La Recherche Medicale (INSERM)|Institut National De La Sante Et De La Recherche Medicale (INSERM)]]: 4 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240409588. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM))]] (20241212) | ||
| + | ** [[20240132547. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM))]] (20240425) | ||
| + | ** [[20240109940. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM))]] (20240404) | ||
=== [[:Category:Anurup Ganguli|Anurup Ganguli of San Diego CA (US)]] === | === [[:Category:Anurup Ganguli|Anurup Ganguli of San Diego CA (US)]] === | ||
* Number of Gene Editing patents: 4 | * Number of Gene Editing patents: 4 | ||
| Line 347: | Line 462: | ||
** [[:Category:VedaBio, Inc.|VedaBio, Inc.]]: 4 patents | ** [[:Category:VedaBio, Inc.|VedaBio, Inc.]]: 4 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[20240254463. ENGINEERED STABLE NUCLEIC ACID-GUIDED NUCLEASES | + | ** [[20240254463. ENGINEERED STABLE NUCLEIC ACID-GUIDED NUCLEASES (VedaBio, Inc.)]] (20240801) |
| − | ** [[20240344044. DELIVERY OF THERAPEUTICS IN VIVO VIA A CRISPR-BASED CASCADE SYSTEM | + | ** [[20240344044. DELIVERY OF THERAPEUTICS IN VIVO VIA A CRISPR-BASED CASCADE SYSTEM (VedaBio, Inc.)]] (20241017) |
| − | ** [[20240110164. DELIVERY OF THERAPEUTICS IN VIVO VIA A CRISPR-BASED CASCADE SYSTEM | + | ** [[20240110164. DELIVERY OF THERAPEUTICS IN VIVO VIA A CRISPR-BASED CASCADE SYSTEM (VedaBio, Inc.)]] (20240404) |
| + | === [[:Category:Addison WRIGHT|Addison WRIGHT of El Cerrito CA (US)]] === | ||
| + | * Number of Gene Editing patents: 4 | ||
| + | * Top companies: | ||
| + | ** [[:Category:Scribe Therapeutics Inc.|Scribe Therapeutics Inc.]]: 4 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240124537. COMPOSITIONS AND METHODS FOR THE TARGETING OF PCSK9 (Scribe Therapeutics Inc.)]] (20240418) | ||
| + | ** [[20240033377. AAV VECTORS FOR GENE EDITING (Scribe Therapeutics Inc.)]] (20240201) | ||
| + | ** [[20240360474. SELF-INACTIVATING VECTORS FOR GENE EDITING (Scribe Therapeutics Inc.)]] (20241031) | ||
| + | === [[:Category:Manuel MOHR|Manuel MOHR of Berkeley CA (US)]] === | ||
| + | * Number of Gene Editing patents: 4 | ||
| + | * Top companies: | ||
| + | ** [[:Category:Scribe Therapeutics Inc.|Scribe Therapeutics Inc.]]: 4 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240124537. COMPOSITIONS AND METHODS FOR THE TARGETING OF PCSK9 (Scribe Therapeutics Inc.)]] (20240418) | ||
| + | ** [[20240033377. AAV VECTORS FOR GENE EDITING (Scribe Therapeutics Inc.)]] (20240201) | ||
| + | ** [[20240360474. SELF-INACTIVATING VECTORS FOR GENE EDITING (Scribe Therapeutics Inc.)]] (20241031) | ||
=== [[:Category:Noah Michael Jakimo|Noah Michael Jakimo of Cambridge MA (US)]] === | === [[:Category:Noah Michael Jakimo|Noah Michael Jakimo of Cambridge MA (US)]] === | ||
* Number of Gene Editing patents: 4 | * Number of Gene Editing patents: 4 | ||
| Line 355: | Line 486: | ||
** [[:Category:Arbor Biotechnologies, Inc.|Arbor Biotechnologies, Inc.]]: 4 patents | ** [[:Category:Arbor Biotechnologies, Inc.|Arbor Biotechnologies, Inc.]]: 4 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[20240301371. CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND METHODS OF USING SAME | + | ** [[20240301371. CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND METHODS OF USING SAME (Arbor Biotechnologies, Inc.)]] (20240912) |
| − | ** [[20240301445. CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND METHODS OF USING SAME | + | ** [[20240301445. CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND METHODS OF USING SAME (Arbor Biotechnologies, Inc.)]] (20240912) |
| − | ** [[20240261435. GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING TRANSTHYRETIN (TTR) AND USES THEREOF | + | ** [[20240261435. GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING TRANSTHYRETIN (TTR) AND USES THEREOF (Arbor Biotechnologies, Inc.)]] (20240808) |
=== [[:Category:Kevin Flanigan|Kevin Flanigan of Columbus OH (US)]] === | === [[:Category:Kevin Flanigan|Kevin Flanigan of Columbus OH (US)]] === | ||
* Number of Gene Editing patents: 4 | * Number of Gene Editing patents: 4 | ||
| Line 363: | Line 494: | ||
** [[:Category:RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL|RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL]]: 4 patents | ** [[:Category:RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL|RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL]]: 4 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[20240261434. PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY | + | ** [[20240261434. PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY (RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL)]] (20240808) |
| − | ** [[20240200066. PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY | + | ** [[20240200066. PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY (RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL)]] (20240620) |
| − | ** [[20240189453. MATERIALS AND METHODS FOR NEUROFIBROMIN 2/MERLIN (NF2) GENE THERAPY | + | ** [[20240189453. MATERIALS AND METHODS FOR NEUROFIBROMIN 2/MERLIN (NF2) GENE THERAPY (RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL)]] (20240613) |
=== [[:Category:Manu Tamminen|Manu Tamminen]] === | === [[:Category:Manu Tamminen|Manu Tamminen]] === | ||
* Number of Gene Editing patents: 4 | * Number of Gene Editing patents: 4 | ||
| Line 372: | Line 503: | ||
** [[:Category:EAWAG, SWISS FEDERAL INSTITUTE OF AQUATIC SCIENCE AND TECHNOLOGY|EAWAG, SWISS FEDERAL INSTITUTE OF AQUATIC SCIENCE AND TECHNOLOGY]]: 1 patents | ** [[:Category:EAWAG, SWISS FEDERAL INSTITUTE OF AQUATIC SCIENCE AND TECHNOLOGY|EAWAG, SWISS FEDERAL INSTITUTE OF AQUATIC SCIENCE AND TECHNOLOGY]]: 1 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[20240158843. ACCURATE AND MASSIVELY PARALLEL QUANTIFICATION OF NUCLEIC ACID | + | ** [[20240158843. ACCURATE AND MASSIVELY PARALLEL QUANTIFICATION OF NUCLEIC ACID (EAWAG, SWISS FEDERAL INSTITUTE OF AQUATIC SCIENCE AND TECHNOLOGY)]] (20240516) |
| − | ** [[20240068010. HIGHLY SENSITIVE METHODS FOR ACCURATE PARALLEL QUANTIFICATION OF VARIANT NUCLEIC ACIDS | + | ** [[20240068010. HIGHLY SENSITIVE METHODS FOR ACCURATE PARALLEL QUANTIFICATION OF VARIANT NUCLEIC ACIDS (Genomill Health Oy)]] (20240229) |
| − | ** [[20240068022. METHODS FOR ACCURATE PARALLEL DETECTION AND QUANTIFICATION OF NUCLEIC ACIDS | + | ** [[20240068022. METHODS FOR ACCURATE PARALLEL DETECTION AND QUANTIFICATION OF NUCLEIC ACIDS (Genomill Health Oy)]] (20240229) |
| − | === [[:Category: | + | === [[:Category:Maroof ADIL|Maroof ADIL of Davis CA (US)]] === |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
* Number of Gene Editing patents: 4 | * Number of Gene Editing patents: 4 | ||
* Top companies: | * Top companies: | ||
** [[:Category:Scribe Therapeutics Inc.|Scribe Therapeutics Inc.]]: 4 patents | ** [[:Category:Scribe Therapeutics Inc.|Scribe Therapeutics Inc.]]: 4 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[20240033377. AAV VECTORS FOR GENE EDITING | + | ** [[20240033377. AAV VECTORS FOR GENE EDITING (Scribe Therapeutics Inc.)]] (20240201) |
| − | ** [[ | + | ** [[20240360474. SELF-INACTIVATING VECTORS FOR GENE EDITING (Scribe Therapeutics Inc.)]] (20241031) |
| − | ** [[20240026386. COMPOSITIONS AND METHODS FOR THE TARGETING OF BCL11A | + | ** [[20240026386. COMPOSITIONS AND METHODS FOR THE TARGETING OF BCL11A (Scribe Therapeutics Inc.)]] (20240125) |
=== [[:Category:Kamel KHALILI|Kamel KHALILI of Bala Cynwyd PA (US)]] === | === [[:Category:Kamel KHALILI|Kamel KHALILI of Bala Cynwyd PA (US)]] === | ||
* Number of Gene Editing patents: 4 | * Number of Gene Editing patents: 4 | ||
| Line 413: | Line 520: | ||
** [[:Category:Temple University - of the Commonwealth System of Higher Education|Temple University - of the Commonwealth System of Higher Education]]: 2 patents | ** [[:Category:Temple University - of the Commonwealth System of Higher Education|Temple University - of the Commonwealth System of Higher Education]]: 2 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[20240271128. RNA GUIDED ERADICATION OF HERPES SIMPLEX TYPE I AND OTHER RELATED HUMAN HERPESVIRUSES | + | ** [[20240271128. RNA GUIDED ERADICATION OF HERPES SIMPLEX TYPE I AND OTHER RELATED HUMAN HERPESVIRUSES (Temple University - of the Commonwealth System of Higher Education)]] (20240815) |
| − | ** [[20240336939. CRISPR INDUCED DISRUPTION OF MOGS GENE | + | ** [[20240336939. CRISPR INDUCED DISRUPTION OF MOGS GENE (TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION)]] (20241010) |
| − | ** [[20240139294. METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION | + | ** [[20240139294. METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION (Temple University - of the Commonwealth System of Higher Education)]] (20240502) |
=== [[:Category:Christian Hinderer|Christian Hinderer of Baltimore MD (US)]] === | === [[:Category:Christian Hinderer|Christian Hinderer of Baltimore MD (US)]] === | ||
* Number of Gene Editing patents: 4 | * Number of Gene Editing patents: 4 | ||
| Line 421: | Line 528: | ||
** [[:Category:The Trustees of the University of Pennsylvania|The Trustees of the University of Pennsylvania]]: 4 patents | ** [[:Category:The Trustees of the University of Pennsylvania|The Trustees of the University of Pennsylvania]]: 4 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[20240307511. AAV9-MEDIATED GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I | + | ** [[20240307511. AAV9-MEDIATED GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I (The Trustees of the University of Pennsylvania)]] (20240919) |
| − | ** [[20240016903. GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE II | + | ** [[20240016903. GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE II (The Trustees of the University of Pennsylvania)]] (20240118) |
| − | ** [[20240024510. GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I | + | ** [[20240024510. GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I (The Trustees of the University of Pennsylvania)]] (20240125) |
| + | === [[:Category:Guangping Gao|Guangping Gao of Worcester MA (US)]] === | ||
| + | * Number of Gene Editing patents: 4 | ||
| + | * Top companies: | ||
| + | ** [[:Category:University of Massachusetts|University of Massachusetts]]: 4 patents | ||
| + | * Recent patents: | ||
| + | ** [[20240076692. MINIGENE THERAPY (University of Massachusetts)]] (20240307) | ||
| + | ** [[20240207370. GENE THERAPY FOR BCAA MODULATION IN MAPLE SYRUP URINE DISEASE (MSUD) (University of Massachusetts)]] (20240627) | ||
| + | ** [[20240243975. USE OF INVERTED TERMINAL REPEATS (ITRS) FROM ADENO-ASSOCIATED VIRUS SEROTYPES 8 AND RH.39 IN GENE THERAPY VECTORS (University of Massachusetts)]] (20240718) | ||
=== [[:Category:Christopher BROWN|Christopher BROWN of Albany CA (US)]] === | === [[:Category:Christopher BROWN|Christopher BROWN of Albany CA (US)]] === | ||
* Number of Gene Editing patents: 4 | * Number of Gene Editing patents: 4 | ||
| Line 429: | Line 544: | ||
** [[:Category:Metagenomi, Inc.|Metagenomi, Inc.]]: 4 patents | ** [[:Category:Metagenomi, Inc.|Metagenomi, Inc.]]: 4 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[20240309404. BASE EDITING ENZYMES | + | ** [[20240309404. BASE EDITING ENZYMES (Metagenomi, Inc.)]] (20240919) |
| − | ** [[20240336905. CLASS II, TYPE V CRISPR SYSTEMS | + | ** [[20240336905. CLASS II, TYPE V CRISPR SYSTEMS (Metagenomi, Inc.)]] (20241010) |
| − | ** [[20240218339. CLASS II, TYPE V CRISPR SYSTEMS | + | ** [[20240218339. CLASS II, TYPE V CRISPR SYSTEMS (Metagenomi, Inc.)]] (20240704) |
| − | === [[:Category: | + | === [[:Category:Angus SIDORE|Angus SIDORE of Oakland CA (US)]] === |
* Number of Gene Editing patents: 4 | * Number of Gene Editing patents: 4 | ||
* Top companies: | * Top companies: | ||
| − | ** [[:Category: | + | ** [[:Category:Scribe Therapeutics Inc.|Scribe Therapeutics Inc.]]: 4 patents |
| − | |||
| − | |||
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240033377. AAV VECTORS FOR GENE EDITING (Scribe Therapeutics Inc.)]] (20240201) |
| − | ** [[ | + | ** [[20240360474. SELF-INACTIVATING VECTORS FOR GENE EDITING (Scribe Therapeutics Inc.)]] (20241031) |
| − | ** [[ | + | ** [[20240026385. ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS (Scribe Therapeutics Inc.)]] (20240125) |
| − | === [[:Category: | + | === [[:Category:Suraj MAKHIJA|Suraj MAKHIJA of San Francisco CA (US)]] === |
* Number of Gene Editing patents: 4 | * Number of Gene Editing patents: 4 | ||
* Top companies: | * Top companies: | ||
| − | ** [[:Category: | + | ** [[:Category:Scribe Therapeutics Inc.|Scribe Therapeutics Inc.]]: 4 patents |
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240033377. AAV VECTORS FOR GENE EDITING (Scribe Therapeutics Inc.)]] (20240201) |
| − | ** [[ | + | ** [[20240360474. SELF-INACTIVATING VECTORS FOR GENE EDITING (Scribe Therapeutics Inc.)]] (20241031) |
| − | ** [[ | + | ** [[20240026385. ENGINEERED CLASS 2 TYPE V CRISPR SYSTEMS (Scribe Therapeutics Inc.)]] (20240125) |
| − | === [[:Category: | + | === [[:Category:Bernd ZETSCHE|Bernd ZETSCHE of Cambridge MA (US)]] === |
* Number of Gene Editing patents: 4 | * Number of Gene Editing patents: 4 | ||
* Top companies: | * Top companies: | ||
| − | ** [[:Category: | + | ** [[:Category:Beam Therapeutics Inc.|Beam Therapeutics Inc.]]: 3 patents |
| + | ** [[:Category:The Broad Institute, Inc.|The Broad Institute, Inc.]]: 1 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240167008. NOVEL CRISPR ENZYMES, METHODS, SYSTEMS AND USES THEREOF (Beam Therapeutics Inc.)]] (20240523) |
| − | ** [[ | + | ** [[20240084364. CRISPR ENZYMES AND SYSTEMS (The Broad Institute, Inc.)]] (20240314) |
| − | ** [[ | + | ** [[20240327813. CRISPR ENZYMES, METHODS, SYSTEMS AND USES THEREOF (Beam Therapeutics Inc.)]] (20241003) |
| − | === [[:Category: | + | === [[:Category:Kristof Vandewalle|Kristof Vandewalle]] === |
| − | * Number of Gene Editing patents: | + | * Number of Gene Editing patents: 4 |
* Top companies: | * Top companies: | ||
| − | ** [[:Category: | + | ** [[:Category:INBIOSE N.V.|INBIOSE N.V.]]: 4 patents |
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240209405. PRODUCTION OF A SIALYLATED OLIGOSACCHARIDE MIXTURE BY A CELL (INBIOSE N.V.)]] (20240627) |
| − | ** [[ | + | ** [[20240035004. VARIANT SUCROSE PERMEASE POLYPEPTIDES (INBIOSE N.V.)]] (20240201) |
| − | ** [[ | + | ** [[20240327888. LACTO-N-BIOSE CONVERTING FUCOSYLTRANSFERASES (INBIOSE N.V.)]] (20241003) |
| − | === [[:Category: | + | === [[:Category:Alim Ladha|Alim Ladha of Cambridge MA (US)]] === |
| − | * Number of Gene Editing patents: | + | * Number of Gene Editing patents: 4 |
* Top companies: | * Top companies: | ||
| − | ** [[:Category: | + | ** [[:Category:ReNAgade Therapeutics Management Inc.|ReNAgade Therapeutics Management Inc.]]: 2 patents |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
** [[:Category:The Broad Institute, Inc.|The Broad Institute, Inc.]]: 1 patents | ** [[:Category:The Broad Institute, Inc.|The Broad Institute, Inc.]]: 1 patents | ||
| + | ** [[:Category:THE BROAD INSTITUTE, INC.|THE BROAD INSTITUTE, INC.]]: 1 patents | ||
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240141382. GENE EDITING COMPONENTS, SYSTEMS, AND METHODS OF USE (ReNAgade Therapeutics Management Inc.)]] (20240502) |
| − | ** [[ | + | ** [[20240084274. GENE EDITING COMPONENTS, SYSTEMS, AND METHODS OF USE (ReNAgade Therapeutics Management Inc.)]] (20240314) |
| − | ** [[ | + | ** [[20240043828. T-DNA MEDIATED GENETIC MODIFICATION (THE BROAD INSTITUTE, INC.)]] (20240208) |
| − | === [[:Category: | + | === [[:Category:Kendra CONGDON|Kendra CONGDON of Durham NC (US)]] === |
| − | * Number of Gene Editing patents: | + | * Number of Gene Editing patents: 4 |
* Top companies: | * Top companies: | ||
| − | ** [[:Category: | + | ** [[:Category:Tune Therapeutics, Inc.|Tune Therapeutics, Inc.]]: 4 patents |
| − | |||
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240052328. COMPOSITIONS, SYSTEMS, AND METHODS FOR REDUCING LOW-DENSITY LIPOPROTEIN THROUGH TARGETED GENE REPRESSION (Tune Therapeutics, Inc.)]] (20240215) |
| − | ** [[ | + | ** [[20240067968. COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION (Tune Therapeutics, Inc.)]] (20240229) |
| − | ** [[ | + | ** [[20240067969. COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION (Tune Therapeutics, Inc.)]] (20240229) |
| − | === [[:Category: | + | === [[:Category:AMIR HASSAN FIROOZI|AMIR HASSAN FIROOZI]] === |
| − | * Number of Gene Editing patents: | + | * Number of Gene Editing patents: 4 |
* Top companies: | * Top companies: | ||
| − | ** [[:Category: | + | ** [[:Category:Chiun Mai Communication Systems, Inc.|Chiun Mai Communication Systems, Inc.]]: 4 patents |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
* Recent patents: | * Recent patents: | ||
| − | ** [[ | + | ** [[20240241290. METALENS ARRAY AND DISPLAY DEVICE HAVING SAME (Chiun Mai Communication Systems, Inc.)]] (20240718) |
| − | ** [[ | + | ** [[20240241293. METALENS ARRAY AND DISPLAY DEVICE HAVING SAME (Chiun Mai Communication Systems, Inc.)]] (20240718) |
| − | ** [[ | + | ** [[20240241380. METALENS ARRAY AND DISPLAY DEVICE HAVING SAME (Chiun Mai Communication Systems, Inc.)]] (20240718) |
== Top Collaborations in Gene Editing == | == Top Collaborations in Gene Editing == | ||
| Line 615: | Line 617: | ||
[[File:Top_20_Cities_for_Gene_Editing_Inventors.png|border|800px]] | [[File:Top_20_Cities_for_Gene_Editing_Inventors.png|border|800px]] | ||
| − | * Cambridge: | + | * Cambridge: 288 inventors |
| − | * San Diego: | + | * San Diego: 78 inventors |
| − | * San Francisco: | + | * San Francisco: 64 inventors |
| − | * Boston: | + | * Boston: 63 inventors |
| − | * New York: | + | * New York: 56 inventors |
| + | * Seattle: 51 inventors | ||
| + | * Durham: 46 inventors | ||
| + | * Seoul: 46 inventors | ||
| + | * Zwijnaarde: 43 inventors | ||
| + | * Shanghai: 39 inventors | ||
* London: 38 inventors | * London: 38 inventors | ||
| − | * | + | * Wuhan: 38 inventors |
| − | * | + | * Oakland: 35 inventors |
| − | + | * Berkeley: 33 inventors | |
| − | * | + | * Worcester: 32 inventors |
| − | * | + | * Daejeon: 31 inventors |
| − | * | ||
| − | |||
* Beijing: 28 inventors | * Beijing: 28 inventors | ||
| − | |||
* Wuxi: 28 inventors | * Wuxi: 28 inventors | ||
| − | * Philadelphia: | + | * Philadelphia: 27 inventors |
| − | + | * Hangzhou: 26 inventors | |
| − | |||
| − | * Hangzhou: | ||
[[Category:Gene Editing]] | [[Category:Gene Editing]] | ||
[[Category:Patent Application Trends by Technology in 2024]] | [[Category:Patent Application Trends by Technology in 2024]] | ||
Latest revision as of 02:07, 13 December 2024
Contents
- 1 Gene Editing Patent Application Filing Activity
- 2 Gene Editing patent applications in 2024
- 3 Top Technology Areas in Gene Editing
- 4 Top Companies in Gene Editing
- 4.1 The Broad Institute, Inc.
- 4.2 The Regents of the University of California
- 4.3 Mammoth Biosciences, Inc.
- 4.4 The Trustees of the University of Pennsylvania
- 4.5 UNIVERSITY OF MASSACHUSETTS
- 4.6 THE BROAD INSTITUTE, INC.
- 4.7 Arbor Biotechnologies, Inc.
- 4.8 Massachusetts Institute of Technology
- 4.9 Scribe Therapeutics Inc.
- 4.10 INBIOSE N.V.
- 5 New Companies in Gene Editing (Last Month)
- 6 Emerging Technology Areas in Gene Editing
- 7 Top Companies in Emerging Gene Editing Technologies
- 8 Top Inventors in Gene Editing
- 8.1 Feng Zhang of Cambridge MA (US)
- 8.2 Sean HIGGINS of Alameda CA (US)
- 8.3 Sarah DENNY of San Francisco CA (US)
- 8.4 Benjamin OAKES of El Cerrito CA (US)
- 8.5 Joeri Beauprez
- 8.6 Jonathan Gootenberg of Cambridge MA (US)
- 8.7 David R. Liu of Cambridge MA (US)
- 8.8 Benjamin Julius RAUCH of San Francisco CA (US)
- 8.9 Omar Abudayyeh of Cambridge MA (US)
- 8.10 Brett T. STAAHL of Tiburon CA (US)
- 8.11 Lucas Benjamin HARRINGTON of San Francisco CA (US)
- 8.12 Chenglong HAO
- 8.13 Fengze TAN
- 8.14 Jian ZHU
- 8.15 James M. Wilson of Philadelphia PA (US)
- 8.16 Natalia SAVELIEVA
- 8.17 Jesse Salk of Seattle WA (US)
- 8.18 Lawrence A. Loeb of Bellevue WA (US)
- 8.19 Michael Schmitt of Seattle WA (US)
- 8.20 Aaron DELOUGHERY of San Francisco CA (US)
- 8.21 David PAEZ-ESPINO of Concord CA (US)
- 8.22 Michael Coyle of Chapel Hill NC (US)
- 8.23 Alexandra Briner Crawley of Cary NC (US)
- 8.24 Tedd D. Elich of Durham NC (US)
- 8.25 Pieter Coussement
- 8.26 Thomas Decoene
- 8.27 Annelies Vercauteren
- 8.28 Isabel COLIN of Oakland CA (US)
- 8.29 Feng ZHANG of Cambridge MA (US)
- 8.30 Théophile OHLMANN
- 8.31 Philippe MANGEOT
- 8.32 Emiliano RICCI
- 8.33 Anurup Ganguli of San Diego CA (US)
- 8.34 Addison WRIGHT of El Cerrito CA (US)
- 8.35 Manuel MOHR of Berkeley CA (US)
- 8.36 Noah Michael Jakimo of Cambridge MA (US)
- 8.37 Kevin Flanigan of Columbus OH (US)
- 8.38 Manu Tamminen
- 8.39 Maroof ADIL of Davis CA (US)
- 8.40 Kamel KHALILI of Bala Cynwyd PA (US)
- 8.41 Christian Hinderer of Baltimore MD (US)
- 8.42 Guangping Gao of Worcester MA (US)
- 8.43 Christopher BROWN of Albany CA (US)
- 8.44 Angus SIDORE of Oakland CA (US)
- 8.45 Suraj MAKHIJA of San Francisco CA (US)
- 8.46 Bernd ZETSCHE of Cambridge MA (US)
- 8.47 Kristof Vandewalle
- 8.48 Alim Ladha of Cambridge MA (US)
- 8.49 Kendra CONGDON of Durham NC (US)
- 8.50 AMIR HASSAN FIROOZI
- 9 Top Collaborations in Gene Editing
- 10 Top US States for Gene Editing Inventors
- 11 Top Cities for Gene Editing Inventors
Gene Editing Patent Application Filing Activity
Gene Editing patent applications in 2024
Top Technology Areas in Gene Editing
Top CPC Codes
- C12N9/22 (No explanation available)
- C12N2310/20 (No explanation available)
- Count: 367 patents
- Example: 20240226246. NOVEL OMNI-50 CRISPR NUCLEASE (EmendoBio Inc.)
- C12N15/86 (No explanation available)
- C12N15/11 (No explanation available)
- C12N2750/14143 (No explanation available)
- Count: 165 patents
- Example: 20240226332. GENE THERAPY FOR TREM2-ASSOCIATED DISEASES AND DISORDERS (Eli Lilly and Company)
- C12N15/907 (No explanation available)
- Count: 124 patents
- Example: 20240226246. NOVEL OMNI-50 CRISPR NUCLEASE (EmendoBio Inc.)
- A61K48/005 (No explanation available)
- C12N2800/80 (No explanation available)
- Count: 104 patents
- Example: 20240226246. NOVEL OMNI-50 CRISPR NUCLEASE (EmendoBio Inc.)
- C12N15/111 (No explanation available)
- C12N15/113 (No explanation available)
Top Companies in Gene Editing
The Broad Institute, Inc.
- Number of Gene Editing patents: 22
- Top CPC codes:
- C12N9/22 (No explanation available): 17 patents
- C12N2310/20 (No explanation available): 16 patents
- C12N15/907 (No explanation available): 11 patents
- Recent patents:
- 20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.) (20241003)
- 20240327933. CORONAVIRUS RAPID DIAGNOSTICS (The Broad Institute, Inc.) (20241003)
- 20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.) (20240208)
The Regents of the University of California
- Number of Gene Editing patents: 19
- Top CPC codes:
- C12N9/22 (No explanation available): 10 patents
- C12N2310/20 (No explanation available): 10 patents
- C12N15/11 (No explanation available): 7 patents
- Recent patents:
- 20240216541. GENE THERAPY FOR ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY (The Regents of the University of California) (20240704)
- 20240023528. ONE-LOCUS INDUCIBLE PRECISION GUIDED STERILE INSECT TECHNIQUE OR TEMPERATURE-INDUCIBLE PRECISION GUIDED STERILE INSECT TECHNIQUE (The Regents of the University of California) (20240125)
- 20240026321. CRISPR-CAS EFFECTOR POLYPEPTIDES AND METHODS OF USE THEREOF (The Regents of the University of California) (20240125)
Mammoth Biosciences, Inc.
- Number of Gene Editing patents: 11
- Top CPC codes:
- C12N9/22 (No explanation available): 8 patents
- C12N15/11 (No explanation available): 6 patents
- C12N2310/20 (No explanation available): 6 patents
- Recent patents:
- 20240084275. COMPOSITIONS AND METHODS OF USING PROGRAMMABLE NUCLEASES FOR INDUCING CELL DEATH (Mammoth Biosciences, Inc.) (20240314)
- 20240218393. VECTORS ENCODING GENE EDITING SYSTEMS AND USES THEREOF (Mammoth Biosciences, Inc.) (20240704)
- 20240327812. FUSION EFFECTOR PROTEINS AND USES THEREOF (Mammoth Biosciences, Inc.) (20241003)
The Trustees of the University of Pennsylvania
- Number of Gene Editing patents: 11
- Top CPC codes:
- C12N15/86 (No explanation available): 7 patents
- A61K48/005 (No explanation available): 5 patents
- C12N2750/14143 (No explanation available): 5 patents
- Recent patents:
- 20240218394. GENE THERAPY FOR OCULAR DISORDERS (The Trustees of the University of Pennsylvania) (20240704)
- 20240316107. Compositions and Methods for Gene Editing in T Cells Using CRISPR/Cpf1 (The Trustees of the University of Pennsylvania) (20240926)
- 20240024510. GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I (The Trustees of the University of Pennsylvania) (20240125)
UNIVERSITY OF MASSACHUSETTS
- Number of Gene Editing patents: 11
- Top CPC codes:
- C12N9/22 (No explanation available): 8 patents
- C12N2310/20 (No explanation available): 7 patents
- C12N15/907 (No explanation available): 5 patents
- Recent patents:
- 20240018479. METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCLE DISEASE WITH IPSC-INDUCED HUMAN SKELETAL MUSCLE STEM CELLS (UNIVERSITY OF MASSACHUSETTS) (20240118)
- 20240175056. PRIME EDITING-BASED SIMULTANEOUS GENOMIC DELETION AND INSERTION (UNIVERSITY OF MASSACHUSETTS) (20240530)
- 20240167029. MODIFIED GUIDE RNAS FOR CRISPR GENOME EDITING (UNIVERSITY OF MASSACHUSETTS) (20240523)
THE BROAD INSTITUTE, INC.
- Number of Gene Editing patents: 10
- Top CPC codes:
- C12N2310/20 (No explanation available): 9 patents
- C12N9/22 (No explanation available): 8 patents
- C12N15/102 (No explanation available): 5 patents
- Recent patents:
Arbor Biotechnologies, Inc.
- Number of Gene Editing patents: 10
- Top CPC codes:
- C12N9/22 (No explanation available): 10 patents
- C12N2310/20 (No explanation available): 10 patents
- C12N15/907 (No explanation available): 5 patents
- Recent patents:
- 20240261435. GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING TRANSTHYRETIN (TTR) AND USES THEREOF (Arbor Biotechnologies, Inc.) (20240808)
- 20240011004. COMPOSITIONS COMPRISING A VARIANT CRISPR NUCLEASE POLYPEPTIDE AND USES THEREOF (Arbor Biotechnologies, Inc.) (20240111)
- 20240409908. NOVEL CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND COMPONENTS (Arbor Biotechnologies, Inc.) (20241212)
Massachusetts Institute of Technology
- Number of Gene Editing patents: 9
- Top CPC codes:
- C12N9/22 (No explanation available): 7 patents
- C12N2310/20 (No explanation available): 7 patents
- C12N15/111 (No explanation available): 5 patents
- Recent patents:
- 20240067957. AUTOCATALYTIC BASE EDITING FOR RNA-RESPONSIVE TRANSLATIONAL CONTROL (Massachusetts Institute of Technology) (20240229)
- 20240067961. SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE) (Massachusetts Institute of Technology) (20240229)
- 20240035031. TARGETED TRANS-SPLICING USING CRISPR/CAS13 (Massachusetts Institute of Technology) (20240201)
Scribe Therapeutics Inc.
- Number of Gene Editing patents: 9
- Top CPC codes:
- C12N2310/20 (No explanation available): 9 patents
- C12N9/22 (No explanation available): 8 patents
- C12N15/907 (No explanation available): 5 patents
- Recent patents:
INBIOSE N.V.
- Number of Gene Editing patents: 9
- Top CPC codes:
- C12N9/1081 (No explanation available): 5 patents
- C12P19/12 (No explanation available): 5 patents
- C12N9/1051 (No explanation available): 5 patents
- Recent patents:
New Companies in Gene Editing (Last Month)
No new companies detected in the last month.
Emerging Technology Areas in Gene Editing
- G06N3/088 (No explanation available)
- Count: 1 patents
- Example: 20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.)
- G06F18/2413 (No explanation available)
- Count: 1 patents
- Example: 20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.)
- G06F18/295 (No explanation available)
- Count: 1 patents
- Example: 20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.)
- G06F18/231 (No explanation available)
- Count: 1 patents
- Example: 20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.)
- G16B40/30 (No explanation available)
- Count: 1 patents
- Example: 20240047011. METHODS FOR IDENTIFYING NOVEL GENE EDITING ELEMENTS (The Broad Institute, Inc.)
- G09B19/00 (No explanation available)
- Count: 1 patents
- Example: 20240046217. TALENT MOBILITY PLATFORM (ADP, Inc.)
- A61L2430/02 (No explanation available)
- Count: 1 patents
- Example: 20240043818. Engineered Cells for Increased Collagen Production (Northeastern University)
- A61L2430/16 (No explanation available)
- Count: 1 patents
- Example: 20240043818. Engineered Cells for Increased Collagen Production (Northeastern University)
- A61L26/0033 (No explanation available)
- Count: 1 patents
- Example: 20240043818. Engineered Cells for Increased Collagen Production (Northeastern University)
- A61L27/24 (No explanation available)
- Count: 1 patents
- Example: 20240043818. Engineered Cells for Increased Collagen Production (Northeastern University)
Top Companies in Emerging Gene Editing Technologies
- The Broad Institute, Inc.: 5 patents
- Northeastern University: 4 patents
- ADP, Inc.: 1 patents
Top Inventors in Gene Editing
Feng Zhang of Cambridge MA (US)
- Number of Gene Editing patents: 21
- Top companies:
- The Broad Institute, Inc.: 12 patents
- THE BROAD INSTITUTE, INC.: 9 patents
- Recent patents:
Sean HIGGINS of Alameda CA (US)
- Number of Gene Editing patents: 9
- Top companies:
- Scribe Therapeutics Inc.: 9 patents
- Recent patents:
Sarah DENNY of San Francisco CA (US)
- Number of Gene Editing patents: 9
- Top companies:
- Scribe Therapeutics Inc.: 9 patents
- Recent patents:
Benjamin OAKES of El Cerrito CA (US)
- Number of Gene Editing patents: 9
- Top companies:
- Scribe Therapeutics Inc.: 9 patents
- Recent patents:
Joeri Beauprez
- Number of Gene Editing patents: 9
- Top companies:
- INBIOSE N.V.: 9 patents
- Recent patents:
Jonathan Gootenberg of Cambridge MA (US)
- Number of Gene Editing patents: 8
- Top companies:
- Massachusetts Institute of Technology: 4 patents
- The Broad Institute, Inc.: 2 patents
- MASSACHUSETTS INSTITUTE OF TECHNOLOGY: 1 patents
- Recent patents:
- 20240067961. SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE) (Massachusetts Institute of Technology) (20240229)
- 20240191223. TYPE VI CRISPR ORTHOLOGS AND SYSTEMS (The Broad Institute, Inc.) (20240613)
- 20240327933. CORONAVIRUS RAPID DIAGNOSTICS (The Broad Institute, Inc.) (20241003)
David R. Liu of Cambridge MA (US)
- Number of Gene Editing patents: 8
- Top companies:
- The Broad Institute, Inc.: 4 patents
- President and Fellows of Harvard College: 2 patents
- President and Fellows of Harvard College: 1 patents
- Recent patents:
- 20240344055. METHODS AND SYSTEMS FOR MODIFYING THE CRUMBS HOMOLOGUE-1 (CRB1) GENE (The Trustees of Columbia University in the City of New York) (20241017)
- 20240110166. EDITING OF CCR5 RECEPTOR GENE TO PROTECT AGAINST HIV INFECTION (President and Fellows of Harvard College) (20240404)
- 20240327872. METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES (The Broad Institute, Inc.) (20241003)
Benjamin Julius RAUCH of San Francisco CA (US)
- Number of Gene Editing patents: 7
- Top companies:
- Mammoth Biosciences, Inc.: 7 patents
- Recent patents:
Omar Abudayyeh of Cambridge MA (US)
- Number of Gene Editing patents: 7
- Top companies:
- Massachusetts Institute of Technology: 4 patents
- MASSACHUSETTS INSTITUTE OF TECHNOLOGY: 1 patents
- THE BROAD INSTITUTE, INC.: 1 patents
- Recent patents:
- 20240132883. RNA-TRIGGERED PROTEIN CLEAVAGE AND APPLICATIONS BY THE CRISPR CAS7-11-CSX29 COMPLEX (Massachusetts Institute of Technology) (20240425)
- 20240093193. DEAD GUIDES FOR CRISPR TRANSCRIPTION FACTORS (The Broad Institute, Inc.) (20240321)
- 20240067961. SYSTEMS, METHODS, AND COMPOSITIONS FOR SITE-SPECIFIC GENETIC ENGINEERING USING PROGRAMMABLE ADDITION VIA SITE-SPECIFIC TARGETING ELEMENTS (PASTE) (Massachusetts Institute of Technology) (20240229)
Brett T. STAAHL of Tiburon CA (US)
- Number of Gene Editing patents: 6
- Top companies:
- Scribe Therapeutics Inc.: 6 patents
- Recent patents:
Lucas Benjamin HARRINGTON of San Francisco CA (US)
- Number of Gene Editing patents: 6
- Top companies:
- Mammoth Biosciences, Inc.: 6 patents
- Recent patents:
- 20240084275. COMPOSITIONS AND METHODS OF USING PROGRAMMABLE NUCLEASES FOR INDUCING CELL DEATH (Mammoth Biosciences, Inc.) (20240314)
- 20240218393. VECTORS ENCODING GENE EDITING SYSTEMS AND USES THEREOF (Mammoth Biosciences, Inc.) (20240704)
- 20240327812. FUSION EFFECTOR PROTEINS AND USES THEREOF (Mammoth Biosciences, Inc.) (20241003)
Chenglong HAO
- Number of Gene Editing patents: 6
- Top companies:
- SHENZHEN METALENX TECHNOLOGY CO.,LTD: 5 patents
- SHENZHEN METALENX TECHNOLOGY CO., LTD: 1 patents
- Recent patents:
- 20240345463. POINT CLOUD PROJECTION SYSTEM (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20241017)
- 20240315540. ENDOSCOPIC PROBE, ENDOSCOPE AND METHOD OF SCANNING CONTROL (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20240926)
- 20240319016. METALENS ARRAY AND WAVEFRONT SENSOR SYSTEM (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20240926)
Fengze TAN
- Number of Gene Editing patents: 6
- Top companies:
- SHENZHEN METALENX TECHNOLOGY CO.,LTD: 5 patents
- SHENZHEN METALENX TECHNOLOGY CO., LTD: 1 patents
- Recent patents:
- 20240345463. POINT CLOUD PROJECTION SYSTEM (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20241017)
- 20240315540. ENDOSCOPIC PROBE, ENDOSCOPE AND METHOD OF SCANNING CONTROL (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20240926)
- 20240319016. METALENS ARRAY AND WAVEFRONT SENSOR SYSTEM (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20240926)
Jian ZHU
- Number of Gene Editing patents: 6
- Top companies:
- SHENZHEN METALENX TECHNOLOGY CO.,LTD: 5 patents
- SHENZHEN METALENX TECHNOLOGY CO., LTD: 1 patents
- Recent patents:
- 20240345463. POINT CLOUD PROJECTION SYSTEM (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20241017)
- 20240315540. ENDOSCOPIC PROBE, ENDOSCOPE AND METHOD OF SCANNING CONTROL (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20240926)
- 20240319016. METALENS ARRAY AND WAVEFRONT SENSOR SYSTEM (SHENZHEN METALENX TECHNOLOGY CO.,LTD) (20240926)
James M. Wilson of Philadelphia PA (US)
- Number of Gene Editing patents: 6
- Top companies:
- Recent patents:
- 20240197916. COMPOSITIONS AND METHODS FOR IN VIVO NUCLEASE-MEDIATED GENE TARGETING FOR THE TREATMENT OF GENETIC DISORDERS (The Trustees of the University of Pennsylvania) (20240620)
- 20240016903. GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE II (The Trustees of the University of Pennsylvania) (20240118)
- 20240024510. GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I (The Trustees of the University of Pennsylvania) (20240125)
Natalia SAVELIEVA
- Number of Gene Editing patents: 6
- Top companies:
- CELL AND GENE THERAPY LTD: 6 patents
- Recent patents:
- [[20240366787. Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of NOS2, NOS3, VIP, KCNMA1, and CGRP genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-NOS2, or Escherichia coli strain SCS110-AF/VTvaf17-NOS3, or Escherichia coli strain SCS110-AF/VTvaf17-VIP, or Escherichia coli strain SCS110-AF/VTvaf17-KCNMA1, or Escherichia coli strain SCS110-AF/V (CELL AND GENE THERAPY LTD)]] (20241107)
- [[20240060083. Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of SHH, CTNNB1, NOG, and WNT7A genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-SHH, or Escherichia coli strain SCS110-AF/VTvaf17-CTNNB1, or Escherichia coli strain SCS110-AF/VTvaf17-NOG, or Escherichia coli strain SCS110-AF/VTvaf17-WNT7A carrying the gene therapy DNA vector, method (CELL AND GENE THERAPY LTD)]] (20240222)
- [[20240325569. Gene therapy DNA vector based on gene therapy DNA vector VTvaf17 carrying the therapeutic gene selected from the group of BDNF, VEGFA, BFGF, NGF, GDNF, NT3, CNTF, and IGF1 genes for increasing the expression level of these therapeutic genes, method of its production and use, Escherichia coli strain SCS110-AF/VTvaf17-BDNF, or Escherichia coli strain SCS110-AF/VTvaf17-VEGFA, or Escherichia coli strain SCS110-AF/VTvaf17-BFGF, or Escherichia coli strain SCS110-AF/VTvaf17-NGF, or Escherichia coli str (CELL AND GENE THERAPY LTD)]] (20241003)
Jesse Salk of Seattle WA (US)
- Number of Gene Editing patents: 6
- Top companies:
- Recent patents:
- 20240368692. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20241107)
- 20240035088. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20240201)
- 20240084385. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20240314)
Lawrence A. Loeb of Bellevue WA (US)
- Number of Gene Editing patents: 6
- Top companies:
- Recent patents:
- 20240368692. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20241107)
- 20240035088. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20240201)
- 20240084385. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20240314)
Michael Schmitt of Seattle WA (US)
- Number of Gene Editing patents: 6
- Top companies:
- Recent patents:
- 20240368692. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20241107)
- 20240035088. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20240201)
- 20240084385. METHODS OF LOWERING THE ERROR RATE OF MASSIVELY PARALLEL DNA SEQUENCING USING DUPLEX CONSENSUS SEQUENCING (UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION) (20240314)
Aaron DELOUGHERY of San Francisco CA (US)
- Number of Gene Editing patents: 5
- Top companies:
- Mammoth Biosciences, Inc.: 5 patents
- Recent patents:
David PAEZ-ESPINO of Concord CA (US)
- Number of Gene Editing patents: 5
- Top companies:
- Mammoth Biosciences, Inc.: 5 patents
- Recent patents:
- 20240271113. EFFECTOR PROTEINS AND METHODS OF USE (Mammoth Biosciences, Inc.) (20240815)
- 20240131187. EFFECTOR PROTEINS, EFFECTOR PARTNERS, COMPOSITIONS, SYSTEMS AND METHODS OF USE THEREOF (Mammoth Biosciences, Inc.) (20240425)
- 20240191281. PROGRAMMABLE NUCLEASES AND METHODS OF USE (Mammoth Biosciences, Inc.) (20240613)
Michael Coyle of Chapel Hill NC (US)
- Number of Gene Editing patents: 5
- Top companies:
- LifeEDIT Therapeutics, Inc.: 5 patents
- Recent patents:
- 20240376456. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20241114)
- 20240401084. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20241205)
- 20240026384. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20240125)
Alexandra Briner Crawley of Cary NC (US)
- Number of Gene Editing patents: 5
- Top companies:
- LifeEDIT Therapeutics, Inc.: 5 patents
- Recent patents:
- 20240376456. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20241114)
- 20240401084. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20241205)
- 20240026384. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20240125)
Tedd D. Elich of Durham NC (US)
- Number of Gene Editing patents: 5
- Top companies:
- LifeEDIT Therapeutics, Inc.: 5 patents
- Recent patents:
- 20240376456. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20241114)
- 20240401084. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20241205)
- 20240026384. RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE (LifeEDIT Therapeutics, Inc.) (20240125)
Pieter Coussement
- Number of Gene Editing patents: 5
- Top companies:
- INBIOSE N.V.: 5 patents
- Recent patents:
Thomas Decoene
- Number of Gene Editing patents: 5
- Top companies:
- INBIOSE N.V.: 5 patents
- Recent patents:
Annelies Vercauteren
- Number of Gene Editing patents: 5
- Top companies:
- INBIOSE N.V.: 5 patents
- Recent patents:
Isabel COLIN of Oakland CA (US)
- Number of Gene Editing patents: 5
- Top companies:
- Scribe Therapeutics Inc.: 5 patents
- Recent patents:
Feng ZHANG of Cambridge MA (US)
- Number of Gene Editing patents: 5
- Top companies:
- The Broad Institute, Inc.: 5 patents
- Recent patents:
- 20240035007. SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH OPTIMIZED FUNCTIONAL CRISPR-CAS SYSTEMS (The Broad Institute, Inc.) (20240201)
- 20240035048. DELIVERY, ENGINEERING AND OPTIMIZATION OF SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTIC APPLICATIONS (The Broad Institute, Inc.) (20240201)
- 20240084364. CRISPR ENZYMES AND SYSTEMS (The Broad Institute, Inc.) (20240314)
Théophile OHLMANN
- Number of Gene Editing patents: 4
- Top companies:
- Recent patents:
- 20240409588. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM)) (20241212)
- 20240132547. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM)) (20240425)
- 20240109940. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM)) (20240404)
Philippe MANGEOT
- Number of Gene Editing patents: 4
- Top companies:
- Recent patents:
- 20240409588. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM)) (20241212)
- 20240132547. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM)) (20240425)
- 20240109940. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM)) (20240404)
Emiliano RICCI
- Number of Gene Editing patents: 4
- Top companies:
- Recent patents:
- 20240409588. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM)) (20241212)
- 20240132547. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM)) (20240425)
- 20240109940. METHODS AND PRODUCTS FOR GENETIC ENGINEERING (Institut National De La Sante Et De La Recherche Medicale (INSERM)) (20240404)
Anurup Ganguli of San Diego CA (US)
- Number of Gene Editing patents: 4
- Top companies:
- VedaBio, Inc.: 4 patents
- Recent patents:
- 20240254463. ENGINEERED STABLE NUCLEIC ACID-GUIDED NUCLEASES (VedaBio, Inc.) (20240801)
- 20240344044. DELIVERY OF THERAPEUTICS IN VIVO VIA A CRISPR-BASED CASCADE SYSTEM (VedaBio, Inc.) (20241017)
- 20240110164. DELIVERY OF THERAPEUTICS IN VIVO VIA A CRISPR-BASED CASCADE SYSTEM (VedaBio, Inc.) (20240404)
Addison WRIGHT of El Cerrito CA (US)
- Number of Gene Editing patents: 4
- Top companies:
- Scribe Therapeutics Inc.: 4 patents
- Recent patents:
Manuel MOHR of Berkeley CA (US)
- Number of Gene Editing patents: 4
- Top companies:
- Scribe Therapeutics Inc.: 4 patents
- Recent patents:
Noah Michael Jakimo of Cambridge MA (US)
- Number of Gene Editing patents: 4
- Top companies:
- Arbor Biotechnologies, Inc.: 4 patents
- Recent patents:
- 20240301371. CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND METHODS OF USING SAME (Arbor Biotechnologies, Inc.) (20240912)
- 20240301445. CRISPR-ASSOCIATED TRANSPOSON SYSTEMS AND METHODS OF USING SAME (Arbor Biotechnologies, Inc.) (20240912)
- 20240261435. GENE EDITING SYSTEMS COMPRISING AN RNA GUIDE TARGETING TRANSTHYRETIN (TTR) AND USES THEREOF (Arbor Biotechnologies, Inc.) (20240808)
Kevin Flanigan of Columbus OH (US)
- Number of Gene Editing patents: 4
- Top companies:
- Recent patents:
- 20240261434. PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY (RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL) (20240808)
- 20240200066. PRODUCTS AND METHODS FOR TREATING MUSCULAR DYSTROPHY (RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL) (20240620)
- 20240189453. MATERIALS AND METHODS FOR NEUROFIBROMIN 2/MERLIN (NF2) GENE THERAPY (RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL) (20240613)
Manu Tamminen
- Number of Gene Editing patents: 4
- Top companies:
- Genomill Health Oy: 3 patents
- EAWAG, SWISS FEDERAL INSTITUTE OF AQUATIC SCIENCE AND TECHNOLOGY: 1 patents
- Recent patents:
- 20240158843. ACCURATE AND MASSIVELY PARALLEL QUANTIFICATION OF NUCLEIC ACID (EAWAG, SWISS FEDERAL INSTITUTE OF AQUATIC SCIENCE AND TECHNOLOGY) (20240516)
- 20240068010. HIGHLY SENSITIVE METHODS FOR ACCURATE PARALLEL QUANTIFICATION OF VARIANT NUCLEIC ACIDS (Genomill Health Oy) (20240229)
- 20240068022. METHODS FOR ACCURATE PARALLEL DETECTION AND QUANTIFICATION OF NUCLEIC ACIDS (Genomill Health Oy) (20240229)
Maroof ADIL of Davis CA (US)
- Number of Gene Editing patents: 4
- Top companies:
- Scribe Therapeutics Inc.: 4 patents
- Recent patents:
Kamel KHALILI of Bala Cynwyd PA (US)
- Number of Gene Editing patents: 4
- Top companies:
- Recent patents:
- 20240271128. RNA GUIDED ERADICATION OF HERPES SIMPLEX TYPE I AND OTHER RELATED HUMAN HERPESVIRUSES (Temple University - of the Commonwealth System of Higher Education) (20240815)
- 20240336939. CRISPR INDUCED DISRUPTION OF MOGS GENE (TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION) (20241010)
- 20240139294. METHODS AND COMPOSITIONS FOR RNA-GUIDED TREATMENT OF HIV INFECTION (Temple University - of the Commonwealth System of Higher Education) (20240502)
Christian Hinderer of Baltimore MD (US)
- Number of Gene Editing patents: 4
- Top companies:
- Recent patents:
- 20240307511. AAV9-MEDIATED GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I (The Trustees of the University of Pennsylvania) (20240919)
- 20240016903. GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE II (The Trustees of the University of Pennsylvania) (20240118)
- 20240024510. GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I (The Trustees of the University of Pennsylvania) (20240125)
Guangping Gao of Worcester MA (US)
- Number of Gene Editing patents: 4
- Top companies:
- University of Massachusetts: 4 patents
- Recent patents:
- 20240076692. MINIGENE THERAPY (University of Massachusetts) (20240307)
- 20240207370. GENE THERAPY FOR BCAA MODULATION IN MAPLE SYRUP URINE DISEASE (MSUD) (University of Massachusetts) (20240627)
- 20240243975. USE OF INVERTED TERMINAL REPEATS (ITRS) FROM ADENO-ASSOCIATED VIRUS SEROTYPES 8 AND RH.39 IN GENE THERAPY VECTORS (University of Massachusetts) (20240718)
Christopher BROWN of Albany CA (US)
- Number of Gene Editing patents: 4
- Top companies:
- Metagenomi, Inc.: 4 patents
- Recent patents:
Angus SIDORE of Oakland CA (US)
- Number of Gene Editing patents: 4
- Top companies:
- Scribe Therapeutics Inc.: 4 patents
- Recent patents:
Suraj MAKHIJA of San Francisco CA (US)
- Number of Gene Editing patents: 4
- Top companies:
- Scribe Therapeutics Inc.: 4 patents
- Recent patents:
Bernd ZETSCHE of Cambridge MA (US)
- Number of Gene Editing patents: 4
- Top companies:
- Beam Therapeutics Inc.: 3 patents
- The Broad Institute, Inc.: 1 patents
- Recent patents:
Kristof Vandewalle
- Number of Gene Editing patents: 4
- Top companies:
- INBIOSE N.V.: 4 patents
- Recent patents:
Alim Ladha of Cambridge MA (US)
- Number of Gene Editing patents: 4
- Top companies:
- ReNAgade Therapeutics Management Inc.: 2 patents
- The Broad Institute, Inc.: 1 patents
- THE BROAD INSTITUTE, INC.: 1 patents
- Recent patents:
- 20240141382. GENE EDITING COMPONENTS, SYSTEMS, AND METHODS OF USE (ReNAgade Therapeutics Management Inc.) (20240502)
- 20240084274. GENE EDITING COMPONENTS, SYSTEMS, AND METHODS OF USE (ReNAgade Therapeutics Management Inc.) (20240314)
- 20240043828. T-DNA MEDIATED GENETIC MODIFICATION (THE BROAD INSTITUTE, INC.) (20240208)
Kendra CONGDON of Durham NC (US)
- Number of Gene Editing patents: 4
- Top companies:
- Tune Therapeutics, Inc.: 4 patents
- Recent patents:
- 20240052328. COMPOSITIONS, SYSTEMS, AND METHODS FOR REDUCING LOW-DENSITY LIPOPROTEIN THROUGH TARGETED GENE REPRESSION (Tune Therapeutics, Inc.) (20240215)
- 20240067968. COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION (Tune Therapeutics, Inc.) (20240229)
- 20240067969. COMPOSITIONS, SYSTEMS, AND METHODS FOR REGULATION OF HEPATITIS B VIRUS THROUGH TARGETED GENE REPRESSION (Tune Therapeutics, Inc.) (20240229)
AMIR HASSAN FIROOZI
- Number of Gene Editing patents: 4
- Top companies:
- Chiun Mai Communication Systems, Inc.: 4 patents
- Recent patents:
- 20240241290. METALENS ARRAY AND DISPLAY DEVICE HAVING SAME (Chiun Mai Communication Systems, Inc.) (20240718)
- 20240241293. METALENS ARRAY AND DISPLAY DEVICE HAVING SAME (Chiun Mai Communication Systems, Inc.) (20240718)
- 20240241380. METALENS ARRAY AND DISPLAY DEVICE HAVING SAME (Chiun Mai Communication Systems, Inc.) (20240718)
Top Collaborations in Gene Editing
Top US States for Gene Editing Inventors
Top Cities for Gene Editing Inventors
- Cambridge: 288 inventors
- San Diego: 78 inventors
- San Francisco: 64 inventors
- Boston: 63 inventors
- New York: 56 inventors
- Seattle: 51 inventors
- Durham: 46 inventors
- Seoul: 46 inventors
- Zwijnaarde: 43 inventors
- Shanghai: 39 inventors
- London: 38 inventors
- Wuhan: 38 inventors
- Oakland: 35 inventors
- Berkeley: 33 inventors
- Worcester: 32 inventors
- Daejeon: 31 inventors
- Beijing: 28 inventors
- Wuxi: 28 inventors
- Philadelphia: 27 inventors
- Hangzhou: 26 inventors
